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 9 
Abbreviations: 10 
COSMIN COnsensus-based Standards for the selection of health Measurement 11 
INstruments. 12 
MPA   measurement property assessment 13 
OT occupational therapist 14 
PT physiotherapist 15 
RCT randomised controlled trial 16 
SLT speech and language therapist 17 
 18 
19 
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 20 
Abstract  21 
Objective: To systematically review methods for measuring adherence used in home-based 22 
rehabilitation trials, and evaluate their validity, reliability and acceptability.  23 
Data sources: Phase 1: We searched CENTRAL, EED and HTA (Jan 2000-April 2013) to 24 
identify adherence measures used in randomised controlled trials of allied health professional 25 
home-based rehabilitation interventions. Phase 2: We searched Medline, Embase, CINAHL, 26 
AMED, PsycINFO, CENTRAL, ProQuest and Web of Science (inception-April 2015) for 27 
measurement property assessments (MPAs) for each measure. 28 
Study selection: Studies assessing the validity, reliability or acceptability of adherence 29 
measures    30 
Data extraction: Two reviewers independently extracted data on participant and measure 31 
characteristics, measurement properties evaluated, evaluation methods and outcome statistics 32 
and assessed study quality using the COSMIN checklist.  33 
Data synthesis: Phase 1:  We included 8 adherence measures (n=56 trials). Phase 2: From 34 
222 MPAs identified in 109 studies, 22 high quality MPAs were narratively synthesised. Low 35 
quality studies were used as supporting data. StepWatch Activity Monitor validly and 36 
acceptably measured short term step count adherence. The Problematic Experiences of 37 
Therapy Scale validly and reliably assessed adherence to vestibular rehabilitation exercises. 38 
Adherence diaries had moderately-high validity and acceptability across limited populations. 39 
The Borg 6-20 scale, Bassett & Prapavessis’ scale and the Yamax CW series had insufficient 40 
validity. Low quality evidence supported use of the Joint Protection Behaviour Assessment 41 
Polar A1 series heart monitors were considered acceptable by one study.  42 
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Conclusions: Current rehabilitation adherence measures are limited. Some possess promising 43 
validity and acceptability for certain parameters of adherence, situations and populations and 44 
should be used in these situations. Rigorous evaluation of adherence measures in a broader 45 
range of populations is needed. 46 
Keywords: Patient compliance, reliability and validity, rehabilitation 47 
PROSPERO ID: CRD42013004084.  48 
49 
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 50 
Adherence is the extent to which a person’s behaviour coincides with agreed clinical 51 
recommendations.1 Documenting participant adherence in clinical practice is necessary to 52 
monitor the patient’s progress and help determine whether improvements (or lack of) is to be 53 
attributed to non/adherence or ineffectiveness of the prescribed therapy. Similarly, within 54 
clinical trials it is essential to measure adherence to answer the same question of attribution at 55 
a larger level, assess the impact of the intervention dose upon effectiveness, and to assist in 56 
identifying non-adherent patient subgroups.2 This is particularly vital within home-based 57 
rehabilitation interventions, where therapists expect greater independent patient engagement 58 
to prescribed therapeutic activities between formal therapy sessions. Prescribed home 59 
activities, e.g. home exercises, are an essential component within many allied health 60 
professional rehabilitation therapies, such as physiotherapy or occupational therapy. This 61 
reflects the increasing focus on functionally relevant rehabilitation, early supported 62 
discharge,3 maximising patient engagement with rehabilitation4 and self-management.5  63 
Documenting adherence within clinical trials and practice can also provide an indication of 64 
the acceptability of an intervention to patients.  65 
Given its vital role, the choice of adherence measurement method(s) should be guided by 66 
rigorous evidence of their respective measurement properties. Three prior systematic reviews 67 
have been undertaken in this area, focussing on: self-report adherence measures in home-68 
based rehabilitation;6 patient or provider adherence questionnaires in physiotherapy7 and 69 
measures assessing adherence to non-pharmacological self-management in musculoskeletal 70 
conditions.8 All concluded that the available trials included largely self-developed 71 
questionnaires that lacked sufficient evidence of measurement properties.6,8,9 A broader 72 
perspective was therefore required to encompass other methods in addition to questionnaires, 73 
based on methods currently used in clinical trials. Consequently, this review aimed 1) to 74 
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identify adherence measurement methods used in rehabilitation clinical trials since 2000 and 75 
2) to evaluate their validity, reliability and acceptability.   76 
 77 
Methods 78 
To address both review aims, we used a two-phase approach.  In Phase 1 we identified 79 
recently used adherence measurement methods, and in Phase 2 we evaluated these methods 80 
according to the level of evidence for their measurement properties.  The review protocol was 81 
registered in PROSPERO (ID CRD42013004084) and is reported according to PRISMA 82 
guidelines.10  83 
 84 
Defining adherence 85 
Adherence is commonly defined in general terms, such as the World Health Organisation 86 
definition: “the extent to which a person’s behaviour – taking medication, following a diet, 87 
and/or executing lifestyle changes, corresponds with agreed recommendations from a health 88 
care provider” (p.3).1 Whilst the breadth of this definition allows it to apply widely across 89 
many therapy types, it lacks the detail required to inform a useful operational definition for 90 
use in clinical practice or trials. Rehabilitation interventions are typically complex in nature 91 
and combine a number of parameters, to which patients may differentially adhere. 92 
Rehabilitation prescriptions, similar to exercise or physical activity prescriptions, appear 93 
often to be characterised by four parameters in reviews or trials: frequency, duration, 94 
intensity and accuracy.11–14  For example, stroke patients seeking to improve mobility may be 95 
asked to carry out three balance exercises for five minutes each seven times a week. Despite 96 
adherence to the frequency of seven times per week, the patient may exercise for a shorter 97 
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duration than recommended, may carry out just one of the three exercises or may carry out an 98 
exercise incorrectly.  99 
Adherence was therefore operationalised within this review as the extent to which individuals 100 
undertake a prescribed behaviour accurately and at the agreed frequency, intensity and 101 
duration (see Figure 1). Measures assessing adherence to one or more of these parameters 102 
were included, in order to make recommendations across specific parameters and types of 103 
rehabilitation. “General adherence” was also included to identify any questionnaires based on 104 
the broader concept only.  105 
 106 
Phase 1 – Identifying currently used adherence measures  107 
Phase 1 aimed to collate a sample of adherence measurement methods used in home-based 108 
rehabilitation randomised controlled trials (RCTs). Rehabilitation is defined as the health 109 
strategy applied by professionals “that aims to enable people with health conditions 110 
experiencing or likely to experience disability achieve and maintain optimal functioning in 111 
interaction with the environment.” (p.282).15 Physiotherapy (PT), occupational therapy (OT) 112 
and speech and language therapy (SLT) rehabilitation interventions were selected as allied 113 
health professionals whose therapies most commonly contain home-based components. We 114 
searched the Cochrane Central Register of Controlled Trials (CENTRAL), the NHS 115 
Economic Evaluation Database and the Health Technology Assessment database in April 116 
2013 as a comprehensive source of rehabilitation clinical trials. We used the keywords 117 
adherence, compliance and rehabilitation (see Supplementary File 1). We limited the review 118 
to post-2000 as it was anticipated that relevant adherence measures developed before 2000 119 
would carry forward into more recent usage. Hand searching was not used as adherence 120 
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research is reported across multiple disciplines and research areas rather than within specific 121 
journals.  122 
 123 
Inclusion criteria: 124 
• Study design: RCTs, including protocols of RCTs 125 
• Participants: adults with a health condition of any duration and severity 126 
• Interventions: rehabilitation interventions including at least one of the 127 
following as part of a prescribed therapeutic regimen: modifications to the home 128 
environment or strategies to improve activities of daily living, home-based physical or 129 
language exercises or home-based interventions led by PTs, OTs or SLTs or an 130 
unspecified professional but the intervention met all other inclusion criteria; 131 
interventions to increase adherence to one of the above interventions.  132 
• Comparators: any 133 
• Outcomes: any method of measuring adherence to the concepts outlined 134 
above, including proxy measures, to the home-based component of the intervention.   135 
• Studies carried out in countries where English is the primary language to 136 
ensure applicability to English-speaking populations.  137 
 138 
Exclusion criteria: 139 
Studies were excluded if they assessed the following: healthcare professional adherence to 140 
guidelines or study protocols; clinic- or hospital-based adherence only; group- or class-based 141 
adherence only; nutritional or pharmacological interventions only; primary prevention or 142 
screening initiatives; increasing physical activity in general rather than prescribed therapy.  143 
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One reviewer screened titles, abstracts and full texts for relevant clinical trials, taking an 144 
inclusive approach and checking with a second reviewer (SL) in cases of uncertainty. Both 145 
reviewers (RF and SL) extracted data from included studies using a standardised data 146 
extraction form, regarding intervention characteristics; sample demographics; adherence 147 
measurement method used and component of adherence measured; adherence definition and 148 
outcome used; assessment location; completion rates; and references to relevant measurement 149 
property studies. In cases of disagreement, consensus was reached through discussion or 150 
consultation with a third reviewer (BW). Risk of bias was not assessed as we aimed to 151 
compile measurement methods rather than utilise the trials’ findings. Titles of adherence 152 
measurement methods identified in Phase 1 contributed to Phase 2.  153 
 154 
Phase 2 – Evaluating the measurement properties of each method 155 
Within Phase 2 we aimed to evaluate the validity, reliability and acceptability of each named 156 
measurement method located in Phase 1, defined as: 157 
i. Validity: whether an instrument measures what it intends to16, including: 158 
a. Criterion validity: the closeness of a measure with the recognised gold 159 
standard or how well it predicts future outcomes.16 160 
b. Construct validity: testing a hypothesised network of relationships and 161 
inferring the validity of the instrument from the results of these tests.16,17  162 
c. Structural validity: the degree to which questionnaire scores reflect the 163 
dimensionality of the constructs measured.18 164 
d. Face validity: the relevance and clarity of the measure at face value 165 
according to respondents or investigators’ assessments.19,20 166 
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e. Content validity: systematic examination of the extent to which the 167 
instrument covers all elements requiring measurement in sufficient detail.19 168 
f. Responsiveness to change: a measure’s ability to detect change, ideally 169 
those that are clinically important.21 170 
ii. Reliability: the extent to which a measure is free from random error.17 171 
a. Test-retest reliability: reproducibility of a measure over a short period of 172 
time where the variable is not expected to change.20 173 
b. Measurement error: the discrepancy between the observable concept 174 
measured and the actual underlying variable.17 175 
c. Inter-rater reliability: the agreement between two or more raters assessing 176 
the same population.20 177 
d. Intra-rater reliability: the agreement between the same rater on the same 178 
subject on the same occasion 22 179 
e. Internal consistency: the homogeneity of scale items 20  180 
iii. Acceptability: the patient’s willingness or ability to complete a measure,23 including 181 
data from any study type regarding wear time or rates (devices), completion rates, 182 
qualitative interviews, focus groups or think aloud studies and survey opinions or 183 
rating scales.24,25  184 
Measurement properties were based on Classical Test Theory concepts with Item Response 185 
Theory (a questionnaire-specific theory that models the relationship between questionnaire 186 
items and the person’s level of the construct26) MPAs include where relevant e.g. internal 187 
consistency, structural validity . Acceptability was considered a third key characteristic as 188 
adherence measures often require participants to wear or complete instruments more 189 
frequently than other outcome measures.  190 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Adherence measures in rehabilitation 
 
11 
 
Medline, CENTRAL, ProQuest Nursing & Allied Health, EMBASE, CINAHL, AMED and 191 
Web of Science Core Collection were searched initially from inception to April 2015 (see 192 
Appendix 1 for Medline example of search terms). An earlier version of this review can be 193 
found as a conference abstract.27 For each measure the title, with synonyms where applicable, 194 
was combined with acceptability search terms and Terwee et al’s28 MPA study precise filter. 195 
Subject headings were adapted for each database. Hand searching and consultation of topic 196 
experts were infeasible in such a diverse topic area and searching for ongoing MPAs was not 197 
possible as clinical trials registries are focussed on trials only.  198 
 199 
Inclusion criteria:  200 
• Participants: adults (healthy or clinical populations). 201 
• Study types: studies assessing one or more MPAs outlined above in relation 202 
to the frequency, intensity, duration, accuracy or general adherence of an exercise or 203 
activity.  204 
• Setting: laboratory and ‘real-world’ assessments.  205 
• Adherence measure: the specific model or questionnaire type listed in Phase 206 
1 only. 207 
• Comparator: any comparator that could be classed or was described as a gold 208 
standard (criterion only) or measured a related aspect to the adherence component 209 
measured (construct only) 210 
 211 
Exclusion Criteria: 212 
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We excluded papers: not written in English; cross-cultural validity assessments, and therefore 213 
studies where the measure was used or administered in a language other than English; where 214 
the relevant measure was used to validate another measure; where the measure assessed 215 
symptoms, functional limitations or total energy expenditure rather than an adherence 216 
parameter; water-based activity; articles focussed on sports science applications rather than 217 
health science; conference abstracts (limited information) or reviews (relevant systematic 218 
review reference lists were screened). 219 
Study screening was undertaken as per Phase 1. Two reviewers (RF and either HS, BF, KT or 220 
PC) independently extracted data regarding: population, MPA type, sample size, activity, 221 
comparator(s) used, statistical methods, results and conclusions. Both independently assessed 222 
study quality using the COSMIN 4-point checklist 29 and resolved disagreements through 223 
discussion. COSMIN scores measurement property studies as Poor, Fair, Good or Excellent 224 
based on their methodological features according to a least-score-counts system. Though this 225 
checklist has limited applicability to electronic measures as it was developed for patient-226 
reported outcome measures, it is the only comprehensive, well-developed checklist currently 227 
available for MPAs. We intended to synthesise studies of all quality; however, due to a large 228 
number of small, lower quality studies, the protocol was refined to include only Excellent or 229 
Good studies in the main narrative synthesis. This ensured that conclusions were based on 230 
high quality evidence, whilst Poor or Fair rated studies were used in a sensitivity analysis to 231 
see if they confirmed, refuted or extended the higher quality study findings. Study authors 232 
were contacted where possible in the event of missing data. 233 
Studies were tabulated according to measurement method, MPA type and parameters of 234 
adherence the method was validated for. We aggregated studies using the Centre for Reviews 235 
and Dissemination’s narrative synthesis approach.30 Whilst statistics such as limits of 236 
agreement are in the original units and so have a more  straightforward interpretation 31, there 237 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Adherence measures in rehabilitation 
 
13 
 
is little consensus as to the interpretation of statistics which give a value between 0 and 1 238 
(e.g. correlations, kappa, alpha). As we did not plan to conduct meta-analyses, we grouped 239 
values to assist comparisons. A minimum acceptable value was not used as we accepted that 240 
this would differ according to the measurement needs of different situations. High values are 241 
generally considered to be >0.70, preferably >0.80 32–35, therefore we used the following cut 242 
offs, based on commonly used rules of thumb, to classify correlations, alpha, kappa and 243 
percentage wear/completion rates:36 244 
• Poor: 0.00-0.19, 0-19%  245 
• Fair: 0.20-0.39, 20-39% 246 
• Moderate: 0.40-0.59, 40-59% 247 
• Good: 0.60-0.79, 60-79% 248 
• Excellent: >0.80, 80-100% 249 
Other acceptability results were descriptively summarised due to the heterogeneity of the 250 
methods used (e.g. qualitative interviews, completion rates).  251 
 252 
Results 253 
Figure 2 shows the flow of studies throughout Phase 1 and 2. 254 
[Figure 2 about here] 255 
 256 
Phase 1- Identifying currently used adherence measures 257 
Within Phase 1, 56 datasets of 59 full texts were included out of 1174 initial references and 258 
209 full texts. Twenty eight were checked with a second reviewer (SL). Interventions were 259 
classified as discipline-specific as per the professional described in the text, and were largely 260 
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physiotherapy-based (n=36). Musculoskeletal conditions (n=27) were most commonly treated 261 
in the included trials. Thirty five single and 21 combinations of adherence measurement 262 
methods were identified (see Table 1). Frequency adherence was most commonly measured 263 
(n=44), followed by duration (n=15), intensity (n=14) and general adherence (n=12). 264 
Accuracy was only measured in four RCTs. Adherence diaries were assumed to measure 265 
frequency only if no further details were given. Common adherence outcomes used were 266 
average percentage sessions (n=17), average number of sessions (n=14) and percentage 267 
achieving minimum adherence levels (n=10).  268 
Seven named methods were identified. One questionnaire used in two studies37,38 was not 269 
named but the RCT reports contained measurement property information. This scale, termed 270 
Bassett & Prapavessis’ scale after the study authors, was included in Phase 2 but as Phase 2 271 
search strategies incorporated measure titles further measurement property searches were not 272 
feasible for this scale. “Cited by” functions did not reveal further studies. We therefore 273 
evaluated the following eight methods in Phase 2, which are summarised in Table 2 along 274 
with their MPAs.  275 
[Table 2 about here] 276 
 277 
Phase 2 – Evaluating the measurement properties of each method 278 
The initial and updated results were combined, de-duplicated and rescreened as necessary. 279 
Out of 6926 hits across both reviews, 869 full texts were screened and 109 studies including 280 
222 MPAs were included (18 articles checked by a second reviewer). After applying 281 
COSMIN criteria 29, 22 Excellent or Good MPAs were included in the synthesis, 153 low 282 
quality studies were used as supporting data and 47 acceptability studies were evaluated. 283 
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These are summarised alongside a description of each measure in Table 2, with details of 284 
each study tabulated in Supplementary File 2. Three MPAs are awaiting further 285 
information.39–41  286 
To summarise, the evidence for most measures was limited. The StepWatch Activity Monitor 287 
appeared to be the most valid measure of adhering to a daily step count, but the evidence base 288 
consisted largely of short-term laboratory studies, was inconsistent across populations and 289 
lacked predictive validity (see Table 2). It appeared to be reliable and acceptable to wear for 290 
one week and up to 28 days. Adherence diaries had good to excellent criterion validity in the 291 
limited populations they were validated in, but lacked predictive validity of functional 292 
outcomes. Evidence for their reliability was scarce, but acceptability ranged from moderate to 293 
excellent (50-100% return rates). Regarding questionnaires, the Problematic Experiences of 294 
Therapy Scale had greater validity, reliability and acceptability for assessing general 295 
adherence than Bassett & Prapavessis’ scale, though both had limited MPAs in single 296 
populations. The Borg 6-20 scale and CW series pedometers had inadequate validity, though 297 
these measures appeared to be reliable. The Joint Protection Behaviour Assessment had low 298 
quality supporting data for validity and reliability, whilst the Polar A1 heart rate monitor 299 
series had good acceptability in healthy adults but no other validity or reliability assessments. 300 
Sensitivity analyses largely confirmed the findings in broader patient populations and 301 
contributed reliability data. 302 
 303 
Discussion 304 
In this systematic review we found that adherence diaries were the most commonly used 305 
measures, usually for assessing adherence to how frequently a home-based behaviour was 306 
carried out. Self-developed questionnaires were also common, whilst most named methods 307 
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were sparsely used. The eight named methods identified had limited evidence, with 308 
suggestions that the StepWatch Activity Monitor and adherence diaries may be valid and 309 
acceptable within certain populations. Other methods lacked measurement properties or were 310 
assessed only in limited populations.    311 
Strengths 312 
As found in previous reviews of adherence to physiotherapy, rehabilitation and self-313 
management adherence systematic reviews, we found an abundance of self-developed 314 
questionnaires and diaries.6,8,9 However, these reviews found little evidence of measurement 315 
properties for any of the included measures. The larger volume found in this review is likely 316 
to arise from including electronic measures and aggregating diaries (often considered as a 317 
single type of measure).  318 
In order to confirm the relevance of the measures considered in Phase 2 above we updated 319 
our Phase 1 search in August 2016. Out of the 41 new studies identified in the update 320 
adherence diaries (34 studies), Step Watch Activity Monitors (2 studies) Yamax CW-701, 321 
Borg 6-20 scale and the Problematic Experiences of Therapy Scale (each 1 study) continued 322 
to be reported. Additional non-named methods were also reported (as in our Phase 1 review) 323 
including sensors in hardware or software (n=5), self-developed questionnaires (n=6), 324 
telephone interviews (n=6), carer reports (n=1) and an accuracy checklist developed for the 325 
study (n=1). Some newly emerging measures were also reported within isolated studies 326 
including the Exercise Adherence Rating Scale, the Omron HJ-720ITC Pocket pedometer, 327 
the Borg CR-10 scale, the Accusplit pedometer, and the Adherence Assessment. These new 328 
methods remain avenues for further review alongside measures developed in non-English 329 
languages, in trials not indexed in CENTRAL or not yet employed in a rehabilitation clinical 330 
trial.  331 
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To our best knowledge this review is the first to provide a rigorous assessment and summary 332 
of multiple types of adherence measures across a broad range of interventions, participants 333 
and professionals. In particular, previous reviews have neglected to evaluate the acceptability 334 
of each measure, which remains a vital part of adherence measurement, particularly when 335 
measures are worn or completed on a daily basis. Comparison across electronic, provider 336 
report and self-report methods, whilst complex, is vital for decision making and so this 337 
review has greater utility than one of a single measure or type of measure. Further strengths 338 
include the two-phase approach which ensured that relevant measures were assessed and the 339 
use of an explicit conceptual underpinning often absent in adherence measurement. We 340 
searched for a wide variety of measurement properties and two reviewers independently 341 
assessed study quality using the COSMIN checklist. Only one main protocol refinement 342 
occurred, which was to include only high quality studies, but this was deemed reasonable as 343 
it allowed recommendations to be made on the basis of the most rigorous evidence.  344 
Limitations  345 
Within Phase 2, some relevant measurement property assessments may not have been located 346 
due to inadequate definition, classification and reporting of these studies. Common 347 
limitations in the evidence base located included small sample sizes and suboptimal statistics 348 
in validity and reliability assessments. Only a small number of included studies were of high 349 
quality. Most were of Fair or Poor quality and used only small sample sizes. A large majority 350 
of the StepWatch studies were carried out in a lab, which limits generalisability to use in a 351 
home-based situation where a wider range of activity is likely to be recorded. Whilst 352 
laboratory environments lessen the clinical applicability of these studies, they were included 353 
as they provided some validity information and for some tools (e.g. the StepWatch Activity 354 
Monitor) assessing criterion validity outside of a laboratory is challenging.  355 
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Other methods were tested in only limited populations e.g. the Borg scale was usually 356 
validated for activities in healthy adults, despite its increasingly common usage in 357 
rehabilitation. Diaries lacked reliability assessments, whilst all measures had a paucity of 358 
reliability, responsiveness to change and predictive validity studies. Acceptability was rarely 359 
formally assessed, despite wear and completion being important components of electronic 360 
devices such as activity monitors or diaries. Defining adequate comparators was also 361 
problematic as some included methods were used to validate others.42 Gold standards were 362 
unavailable for some types of rehabilitation activity or for assessing adherence to behaviour 363 
accuracy.   364 
Implications for clinical practice 365 
When selecting adherence measures for use in clinical trials or clinical practice, conceptual 366 
adherence definitions need to be utilised. This permits a measure to be selected according to 367 
the level of rigorous evidence of measurement properties available for the relevant 368 
components. The main recommendations for using adherence measures in clinical trials and 369 
practice are summarised in Table 3. Most measures were validated in specific participant 370 
populations and prior to using a measure, clinicians should check it is validated for that 371 
population. Consequently our findings are likely to have the greatest relevance to 372 
physiotherapy and exercise-based interventions, as this was where most measures were used 373 
and evaluated, though some measures (e.g. adherence diaries) were used across all 374 
intervention types.  375 
[Table 3 about here] 376 
 377 
Implications for future research 378 
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Further well-designed, adequately powered studies, particularly reliability studies, evaluating 379 
a measure in therapeutic situations are required to inform future adherence measure selection. 380 
Formal qualitative evaluations by service users are required to further assess acceptability 381 
studies and better reporting of quantitative acceptability data. Identifying the most suitable 382 
measures for different populations will optimise their use in trials and clinical practice. 383 
Furthermore, this review showed that reviewing existing electronic measures (e.g. 384 
pedometers) warrants further investigation to determine their validity and acceptability for 385 
measuring adherence. The development of new questionnaires based upon a thorough 386 
adherence conceptualisation that takes accuracy or intensity into account may also be 387 
valuable. However current methods also offer potential for development and testing. This 388 
should be prioritised to avoid the multitude of self-developed questionnaires that are not 389 
comparable, as identified in the first phase of this review. Utilising adherence measures in 390 
RCTs presents further opportunities to collect feasibility, acceptability and MPA data 391 
regarding adherence measures. These should be reported clearly or separately to enable 392 
location of this data in future reviews.  393 
 394 
Conclusion 395 
Currently, there is no gold standard of adherence measurement for home-based therapies. 396 
Methods included in this review are limited by the quality of evidence of their measurement 397 
properties or their limited applicability across interventions. However, in light of the 398 
available evidence, StepWatch Activity Monitors are likely to be valid and acceptable to 399 
assess adherence to walking interventions, adherence diaries can approximate adherence to 400 
intervention frequency and duration and the Problematic Experiences of Therapy Scale can 401 
validly and reliably assess general adherence across vestibular rehabilitation populations. 402 
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Further study into which measures are most suitable for intervention parameters and patient 403 
populations and clearer reporting is required.  404 
 405 
 406 
407 
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Table 1. Number of measures found in Phase 1, by type and adherence parameter measured 
Measurement Type(s) n Freq Dur In Accu Gen Unclear Ref Named Methods 
Questionnaires (patient) 11 3 2 0 0 7 0 1–11 Problematic Experiences of Therapy Scale 
Questionnaire (provider) 2 0 0 0 1 1 0 12,13 Joint Protection Behaviour Assessment 
Diary 20 18 2 2 0 1 1 14–33 Adherence diary 
Electronic method 1 1 0 0 0 0 0 34 - 
Telephone interview 1 1 0 0 0 0 0 35 - 
Questionnaire (patient and provider) 4 3 2 0 3 1 0 36–39 - 
Diary + provider questionnaire 2 2 0 1 0 1 0 40,41 Adherence diary 
Diary + patient questionnaire 1 1 0 1 0 0 0 42 Adherence diary 
Diary + telephone interview 3 3 0 1 0 1 0 43–45 Adherence diary 
Diary + heart rate (self-assessed) 2 2 1 2 0 0 0 46,47 Adherence diary 
Diary  + electronic method 3 3 2 1 0 0 0 48–50 
StepWatch Activity Monitor 
Yamax Digiwalker CW-701 
Adherence diary 
Diary + telephone interview + questionnaire 1 1 1 1 0 0 0 51 Adherence diary 
Diary + telephone interview + electronic method 1 1 1 1 0 0 0 52 
A1 & FS1 heart rate monitors 
Adherence diary 
Diary + Borg rating of perceived exertion 1 1 1 1 0 0 0 53 
Borg 6-20 RPE  
Adherence diary 
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Diary + Borg rating of perceived exertion + self-
assessed heart rate 
2 2 2 2 0 0 0 54,55 
Borg 6-20 RPE  
Adherence diary 
Diary + telephone interview + Borg rating of 
perceived exertion + self-assessed heart rate 
1 1 1 1 0 0 0 56 
Borg 6-20 RPE  
Adherence diary 
Key: n=number of trials containing this measure; Freq=frequency, Dur=duration, In=Intensity, Accu=accuracy, Gen=general adherence, Ref=reference. The reference list 
for included studies can be found in Supplementary File 3. 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Table 2. Summary of each included measure and its measurement properties 
Measure Description Validity Reliability Acceptability 
StepWatch 
Activity 
Monitor 
(SAM) 
Research-grade ankle-worn 
activity monitor.57 Described as 
a pedometer, accelerometer or 
activity monitor as the internal 
mechanisms have not been 
disclosed.58   
High quality studies (n=5): Small percentage error and 
mean bias and high percentage accuracy compared to 
direct observation for measuring step counts in healthy 
populations, individuals with COPD and individuals 
with MS in laboratory settings.59–61 Fair predictive 
validity in persons with intermittent claudication for 
changes in Peak Walking Time.48  
High quality studies (n=0)  
 
 
 
N=24. Highly acceptable across 
populations for 1-28 days’ wear 
(most commonly worn for 1 week), 
including persons with MS, TKA, 
neurological conditions, sarcoma, 
lower limb prosthesis, knee OA and 
older, sedentary and obese adults. 
In most studies >90% patients 
complied with SAM wear, but this 
was variable in stroke survivors and 
lower in persons with dementia, 
persons with intermittent 
claudication and healthy adults.48,62–
77
 Most wore the SAM for >6 out of 
7 days per week63,66,78–80 and >11 
hours per day.69,80,81  
Low quality studies (n=20): Small mean bias and percentage 
error and high percentage accuracy were confirmed in older 
adults, healthy volunteers and individuals with COPD, 
neurological conditions and mobility limitations).82–98 Lower 
validity in persons with dementia,77 cycling activity,86 
outdoor walking on a paretic limb95 and when attached to a 
cane.98 Moderate construct validity for activity intensity 
compared to a diary.85 
Low quality studies (n=14): Excellent 
test-retest reliability for step counts 
same day to 3 weeks apart in the lab 
or home/ community in persons who 
are healthy or with neurological 
conditions (wider LOA in 
community).62,72,75,77,85,94,97,99–101 
Excellent inter-rater reliability in 
healthy adults.87 
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Problematic 
Experiences 
of Therapy 
Scale 
(PETS) 
12-item scale measuring 
general non-adherence - the 
degree to which socially 
acceptable reasons prevented 
patients adhering e.g. symptom 
severity/aggravation, efficacy 
doubts, practical challenges.102 
High quality studies (n=2): Excellent structural 
validity in two populations with chronic dizziness 
from vestibular conditions.103   
High quality studies (n=2): 
Excellent internal consistency in 
two populations with dizziness.103 
N=1. High completion rates in a 
Meniere’s disease rehabilitation 
study (225/240)11. 
Low quality studies (n=3): The PETS could differentiate 
between self-identified rehabilitation adherers or 
maintainers in Meniere’s disease and dizziness 
patients.11,103 
Low quality studies (n=0) 
Adherence 
diaries (AD) 
ADs were defined by their 
function of regular (usually 
daily) patient self-report of an 
activity. All AD types were 
aggregated.  
High quality studies (n=6): Moderate-excellent 
criterion validity for measuring adherence to exercise 
frequency and duration compared to a heart rate 
monitor, pedometers and radiofrequency 
identification card system in sedentary women, older 
adults, cancer patients and pregnant women.104–107 
Fair to no predictive validity for walking adherence 
and changes in fitness in sedentary women106. Good 
construct validity was found compared to the 
Physical Activity Questionnaire in cancer patients.105 
High quality studies (n=0). 
 
N=19. Ranged evenly from 
moderate to high (50-100% return 
rates) across a variety of patient 
populations recording adherence 
from 2 weeks to 12 
months.14,21,24,25,29,32,33,54,65,105,108–116 
Higher return rates were found in 
persons with TKA, systematic 
sclerosis, heart failure, coronary 
heart disease, diabetes, Crohn’s, 
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Low quality studies (n=19): Good to excellent criterion 
validity compared to a range of objective comparators in 
varied populations (older adults, knee arthroplasty patients, 
individuals with pain conditions, brain injury and 
SLE).65,117–122 Low to moderate predictive validity for 
functional outcome measures in individuals with COPD, 
sedentary women, individuals with radial fracture, total 
knee arthroplasty patients and patients with implantable 
cardiac defibrillators.65,109,123–125. Moderate to good 
construct validity for exercise-related constructs in 
sedentary women and healthy adults, but lower validity for 
behavioural constructs in persons with Huntingdon’s 
disease and sedentary women,. 125–128 Adherence predicted 
maintenance in sedentary women.129 Diaries were 
responsive to short-term adherence changes in pulmonary 
rehabilitation.130 
Low quality studies (n=1): Good test-
retest reliability in pregnant 
women.104 
elbow pain and osteoarthritis. 
Lower (50-75%) return rates were 
found in stroke survivors and 
patients with rotator cuff tears, risk 
factors for diabetes and after stem 
cell transplant. Mixed return rates 
were found in persons with COPD 
and back pain. Strategies that 
appeared to have a higher return 
rate included remuneration,25 
weekly collection65 and weekly 
review115. Monthly collection did 
not engender particularly high 
return rates108 and studies using 
reminders had mixed return 
rates.29,33,105,112 
Bassett & 
Prapavessis’ 
Self-report scale measuring 
general adherence (rated 1-5) to 
5 dimensions of home-based 
High quality studies (n=2): Poor predictive validity 
for adherence and functional outcomes in patients 
with ankle sprains.2 Fair construct validity compared 
High quality studies (n=1): Good 
internal consistency between scale 
items in patients with ankle 
N=0. 
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scale physiotherapy: exercises, ice, 
rest, strapping and elevation.3  
to intentions to adhere in patients with ankle sprains.2 sprains.2  
 
Low quality studies (n=0) Low quality studies (n=1): Good 
internal consistency in patients with 
ankle sprains.3 
Borg 6-20 
rating of 
perceived 
exertion 
scale 
Simple 15-grade scale of self-
reported exertion commonly 
used in rehabilitation, exertion 
testing and training.131 Only 
single estimates of intensity for 
one activity were included as 
the most relevant to 
rehabilitation adherence 
recording. 
High quality studies (n=3):  Fair criterion validity 
compared to a heart rate monitor in older adults in 
two activities.132 Fair construct validity compared to 
other walk parameters (e.g. gait speed).133 
High quality studies N=0. 
 
N=0.  
Low quality studies (n=26): Poor to excellent criterion 
validity compared to objective intensity measures in 
healthy adults and pregnant women.134–143 Low construct 
validity with walking distance travelled in patients with MS 
and stroke survivors18,144 but good with speed and function 
in healthy adults with a foot orthosis and patients with 
MS.18,145 Responsive to changes in walking, exercise and 
ADL intensity in healthy adults.137,143,146–150 Content 
validity in patients with brain injury and low back pain and 
Low quality studies (n=5): Good test-
retest reliability in ADLs, walking, 
resistance training and cycling in 
healthy adults and individuals with 
MS.18,141,142,146,149,152 
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healthy students.151 
Yamax 
Digiwalker 
CW series 
Yamax pedometer which 
records and displays the 
number of steps taken. It has a 
two week memory and a three 
year battery life.153 All CW 
series contain the same internal 
mechanisms and so all were 
included.  
High quality studies (n=1): Limited criterion validity 
compared to a GT1M ActiGraph accelerometer in 
pregnant women (overcounted at high step rates and 
undercounted at low step rates). Moderate to good 
‘active’ and ‘inactive’ classifications.154 
High quality studies (n=0) 
 
 
N=1. CW-701 had data for 58/61 
pregnant women for four days’ 
wear.154 
Low quality studies (n=1): Poor criterion validity (high 
percentage error) in older adults.155 
Low quality studies (n=1) Good inter-
rater reliability in older adults.155 
Joint 
Protection 
Behaviour 
Assessment 
(JPBA) 
20-task observational scale 
assessing performance accuracy 
of arthritis joint protection 
behaviours when making a hot 
drink and snack in a kitchen.156 
Behaviours are graded as 
correct, partially correct or 
High quality studies (n=0)  
 
High quality studies (n=0)  N=1. 83/127 individuals with 
rheumatoid arthritis agreed to be 
recorded performing the JPBA.12 
Low quality studies (n=6): Fair construct validity with 
hand impairment,156,157 but higher with pain, perceived 
helplessness and reduced grip strength in persons with 
rheumatoid arthritis.156,158 Responsive to changes in joint 
protection training in healthy adults.159 Good face and 
Low quality studies: Excellent test-
retest, inter- and intra-rater reliability 
and internal consistency in healthy 
adults and individuals with 
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incorrect and converted to a 
percentage score.156 
content validity to researchers and OTs.156 rheumatoid arthritis.156,159 
Polar A1 
series heart 
rate 
monitors 
A family of Polar heart rate 
monitors. The models from this 
family with the same T31 
transmitter include the FS1, A1, 
FT1, FT4, FT60, FT7 and 
RCX5. All these models were 
included in this review, though 
the A1 and FS1 may no longer 
be in production.160 
High quality studies (n=0) 
 
High quality studies (n=0). 
 
N=1. The Polar FT60 was used in 
76% of exercise session by healthy 
adults. Interviews showed that 
adults found the polar monitor 
motivational, fun and increased 
understanding of exercise. 
However, it was unsuitable for 
certain sports, could be forgotten 
and the guidance was not always 
applicable for people.161   
Low quality studies (n=0) Low quality studies (n=0) 
The reference list for included studies can be found in Supplementary File 3. 
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Table 3. Implications for adherence measures identified in this review 
Measure Implications from this review 
StepWatch 
Activity Monitor 
 Valid for assessing step frequency in persons with COPD and multiple 
sclerosis, but lower predictive validity and in persons with dementia and 
irregular walking activity (e.g. outdoor walking on a paretic limb) 
 Likely to be reliable for use in the community in persons with 
neurological conditions (e.g. stroke survivors, persons with 
Parkinson’s), but this is low quality evidence 
 Acceptable for 7 days wear in persons with neurological conditions and 
knee osteoarthritis and older, sedentary or obese adults 
Problematic 
Experiences of 
Therapy Scale 
 Can be recommended in chronic dizziness populations arising from 
vestibular conditions and where barriers and facilitators require 
assessment  
 Requires testing in a wider variety of populations  
Adherence diaries  Can be used with high validity for recording activity frequency in 
sedentary women, older adults, cancer patients and pregnant women and 
potentially individuals with pain conditions, brain injury, SLE or after 
total knee arthroplasty   
 Lacks predictive validity of functional outcomes 
 Requires further reliability testing 
 Mixed, moderate to excellent return rates across a wide variety of 
populations. Remuneration, weekly collection and weekly review 
appeared to increase completion rates; monthly collection and reminders 
had mixed results  
Bassett & 
Prapavessis’ scale 
 Not currently recommended to assess general adherence: some 
reliability in ankle sprain populations but low construct validity  
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Borg 6-20 rating 
of perceived 
exertion scale 
 Not currently recommended to assess intensity adherence: only fair 
validity in older populations, though may be reliable and responsive to 
change  
Yamax 
Digiwalker CW 
series 
 May be acceptable but cannot be recommended above other measures as 
it lacks evidence of good validity 
 Pedometer models with good supporting evidence should be selected 
Joint Protection 
Behaviour 
Assessment 
 Recommended for assessing accuracy adherence of joint protection 
behaviour in patients with rheumatoid arthritis, though evidence is 
limited  
Polar A1 heart 
rate monitor 
series 
 May be acceptable to healthy adults but not currently recommended due 
to a lack of evidence 
 Heart monitor models with good supporting evidence should be selected 
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1174 titles and abstracts screened
209 full texts screened
150 full texts excluded:1 unavailable (thesis)4 duplicates21 not rehabilitation intervention26 not PT, OT or SLT-led54 non-English measures27 no home-based intervention component11 adherence not measured4 not a RCT2 conference abstracts
59 full texts of 56 datasets included
965 titles and abstracts excluded as irrelevant
Conditions: Musculoskeletal 27Neurological 8Cardiovascular 5Urinary 4Other 10
Intervention type: PT 36OT 5PT + OT 5SLT 1
8 methods extracted:1. StepWatch Activity Monitor (SAM)2. Adherence Diaries (AD)3. Borg 6-20 rating of perceived exertion(RPE) scale4. Bassett & Prapavessis’ Scale (B&P)5. Joint Protection Behaviour Assessment(JPBA)6. Problematic Experiences of TherapyScale (PETS)7. Polar A1 series Heart Rate Monitors8. Yamax Digiwalker CW series pedometer
108 studies included145 MPAs quality assessed
6064 Irrelevant references excluded6926 original titles and abstracts from initialreview and update screened
High quality MPAs: 20SAM n=5PETS = 4AD n=5B&P Scale n=2CW series = 1Borg 6-20 RPE n=3JPBA = 0A1 series = 0
Phase1
Phase2
868 full texts screened
757 full texts excluded:103 conference abstracts12 criterion8 duplicates18 irrelevant populations77 non-English scale/measure versions207 not MPA125 recording irrelevant activity173 incorrect model or scale version9 unable to source full text16 insufficient MPA information9 paper not in EnglishN=3 awaiting further information
Low quality MPAs: 79SAM n=20PETS = 3AD n=7B&P Scale n=1CW series = 1Borg 6-20 RPE n=39JPBA = 8A1 series = 0
Acceptability studies: 46SAM n=24 (q.1)PETS = 1AD n=18B&P Scale n=0CW series = 1Borg 6-20 RPE n=0JPBA = 1A1 series = 1
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Supplementary File 2. Table of included validity, reliability and acceptability studies.  
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
StepWatch Activity Monitor high quality studies (n=5) 
Feito 
2012a162 
Crit val F, I n=65, healthy volunteers, full 
sample (n=71): normal=27.8yrs 
(8.0), overweight=34.6yrs (14.2), 
obese=31.5yrs (11.1), 55%f  
Lab; 5 minute walk on 
motorized treadmill at 3 
different speeds (40, 67 and 
94 m/min).  
Trained observer with hand 
tally counter 
Mean bias close to zero with 95% prediction 
interval: ±8 steps/min 
95-102% steps recorded across different 
speeds. Pearson correlations: slow speed 
r=0.635, moderate speed r=0.500, fast speed 
r=0.558 (all p<0.001) 
G 
Feito 
2012b163  
Crit val F, I n=56, healthy individuals with a 
range of BMI values, 
normal=28.3yrs (10.5), 
overweight=31.2yrs (9.9), 
obese=29.0yrs (7.9), 50%f 
Lab; 5 x 100 step walks on a 
treadmill at different speeds 
(40, 54, 67, 80 and 94 
m/min) 
Trained observer with hand 
tally counter 
100±1% accuracy at slowest speed, >97% 
accuracy at faster speeds. No effect of BMI.  
G 
Hiatt 201148 Crit val D n=62, intermittent claudication 
patients randomised to take 
propionyl-L-carnitine or placebo, 
G1 n=30, 66.6yrs (8.8), 17%f, G2 n-
32 67.4yrs (8.7), 38%f 
Home/community; 30-50 
min walking 2-3 times per 
week; daily activities for 7 
days at screening, 3 mo and 
6 mo 
Change in Peak Walking 
Time between baseline and 
6mo 
Changes in SAM ambulatory activity r=0.34 
(p=0.013) 
Changes in SAM dose (mins of exercise) 
r=0.259 (p=0.048) 
G 
Moy 2012164 Crit val F n=127, stable COPD patients >40, Lab; 244m walking course Observer Mean bias (95% LOA): +3 steps (-13.53 to G 
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age, %female) 
Activity Comparator Statistic and outcome Qual 
71.0yrs (8.0), 2%f at usual speed  20.11 steps). >90% accuracy in 133/134 
participants. No effect of BMI.  
Sandroff 
201461 
Crit val F n=63, ambulatory individuals with 
multiple sclerosis, 50.7yrs (9.2), 
76%f 
Lab; 3 x 6min walk test 
around a rectangular 
hallway at comfortable, fast 
and slow walking speeds 
Direct observation by 
research assistant using 
hand tally counter 
Comfortable walking speed = 99.8% 
accuracy, fast 99.9%, slow 99.0%. High 
disability and low speed were less accurate. 
G 
StepWatch Activity Monitor low quality studies (n=35) 
Algase 200377 Crit val D N=40, individuals with dementia, (all 
subject n=178) 85.3 (6.3), 75%f 
  
Nursing home; duration of 
wandering in two 4hr periods  
Trained observers recording 
using a bar code reader 
Multiple regression controlled for age, sex and 
mini-mental state examination score: SAM 
predicted 63.6% of the variance in time spent 
wandering (p<0.001). Time in motion 16.8% SAM 
vs 15.4% observation.  
P 
Bergman 
2008165 
Crit val F N=21, older adults living in assisted 
living facilities, 78.6 (13.1), 76%f 
Assisted living facility; walking 
course, 161m walk at a self-
selected pace  
Observer with hand tally 
counter 
Mean bias = -11.3 (SE 2.56) (overestimation) 
(p<0.001), 95% prediction interval = -18.01 to -
4.65.  
Correlations r2=0.99 (p<0.001) 
P 
Bowden 
2007101 
Crit val F n=11, individuals with incomplete 
spinal cord injury with no more than 
minimal assistance required for 
walking,  45.5 (range 21-63), 18%f 
Lab; 1 x 6 minute walk test at 
usual pace over series of 
hallways, 2 x 10 minute walk 
tests at self-selected pace, 
completed at 2 different times 
Observer with manual 
handheld counter 
Percentage accuracy (smaller quantity as 
percentage of larger quantity) 6 minute walk test 
= 97%, 10 minute walk test = 97% 
P 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
in randomised order (4 hrs - 1 
week later) 
Busse 200985 Crit val F n=18, healthy volunteers, 26.1 (range 
22-39), gender NR 
Lab; Walking an indoor circuit 
for ~10mins (200m), including 
sit-to-stand transitions, 
completion of kitchen tasks and 
shoe removal; and an outdoor 
circuit for ~20mins (1100m), 
including uneven ground, lifts, 
ramps 
Observer of videotaped walk 
using handheld step counter by 
one researcher with excellent 
intra-rater reliability. Overall  
ICC=0.99 for intra-rater 
reliability, but poor inter-rater 
reliability (ICC 0.26)  
Indoor: mean (SD) dif = 5.76% (5.18). LOA = -4.6 
to 16.2 steps.  
Outdoor: mean (SD) dif = 2.82% (7.47). LOA -12.2 
to 17.8 steps.  
P 
Percentage accuracy: Indoor = 96.1% (3.5), 
outdoor = 99.6% (1.1).  
Percentage error: indoor = 3.9% (3.5), outdoor = 
0.4% (1.1) 
Carr 201286 Crit val D, I N=36, healthy adults, 23 (3.7), 55%f Lab; 60min testing session 
including 6 sedentary and light 
activity activities for 8 min each 
(middle 6min compared)  
Observer watching activities for 
fidelity 
Percentage accuracy for light intensity:   
Walking 1.0mph: 86.1%. Pedalling 7.0mph 54.4%. 
Pedalling 15.0mph 23.5%. Root mean square error 
for minutes correctly coded = 3.33min  
F 
Ford 201092 Crit val F n=12, individuals with Parkinson's 
disease, 67.2 (SD NR), 8.3%f 
Lab; 1 min walk around the lab Single observer   Percentage accuracy 98% P 
Foster 200587 Crit val F n=20, healthy adults 50% lean 30 (13), 
50% obese 32 (7), age range = 21-51yrs, 
50%f  
Lab; 15min walks at 1, 2 and 3 
mph each. Level ground 
walking at 1 and 1.85mph each 
for 25min.  
Single observer using electronic 
counter 
Percentage accuracy 99.7% ±0.67 P 
ICC=0.9995 
Fulk 201493 Crit val F  n=26, diagnosis of stroke or traumatic Lab; 2-minute Walk Test at Observed step count of videoed Mean difference = 4.7 steps (1.11-8.35). No P 
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age, %female) 
Activity Comparator Statistic and outcome Qual 
brain injury, able to walk with minimal 
assistance, able to follow study 
commands and give informed consent. 
(full sample n=50) 52.9 (15.1), 32%f 
normal, comfortable pace with 
SAM on less affected side 
walk on two separate occasions 
(ICC=0.99),with first count used 
in analysis 
relationship between SAM error and gait speed, 
Berg balance scale or Fugl-Meyer score  
ICC=0.97 (0.92-0.99) 
Hartsell 
200288 
Crit val F N=10, healthy adults, 43.2 (14.1), mixed 
(NR).   
Lab; walking course; 4x530m 
walk in athletic shoes or 
fibreglass cast (TCC) on one leg, 
over flat ground and stairs each 
at self-selected pace 
Mean of 2 observers (r=0.9923-
0.9999) 
Percentage error:  flat surface: athletic shoe 
0.136%, TCC 0.206%. Stairs: -3.648% athletic shoe 
and -5.697% TCC (undercounting).  
ANOVA: significant effects for walking surfaces. 
P  
Karabulut 
200589 
Crit val F, I, 
A 
 
N=20, healthy adults, 28 (3.7), 50%f Lab; treadmill; 3min walks at a 
variety of speeds, 3min each of 
heel tapping, leg swinging, cycle 
ergometer and (n=10) driving.  
Observer with hand tally 
counter (2nd min only)  
Mean bias = 0.9 steps min-1, prediction interval = -
2.3 to +4.1 steps min-1. Mean step counts within 
1% at all speeds. SAM responsive to heel tapping, 
leg swinging and cycling but not driving.  
P 
Macko 200294 Crit val F 
 
n=16, >55 yrs of age with remote 
ischemic stroke (>6 months), with 
residual hemiparetic gait deficits and 
some preserved capacity for 
ambulation, 67 (7), mixed (NR) 
Rehabilitation centre; walking 
course; 2x6min floor walk at 
self-selected pace, 2x1min floor 
at self-selected comfortable and  
fastest pace using normal 
adaptive device/orthosis  
Observer with hand tally Percentage accuracy:  
self-selected pace 98.5%±-1.0 (P<0.01),  
fast walking pace 97.7±-2.0* (p<0.01)  
First 6min walk 98.8±1.1 
2nd 6min walk 98.7±1.2 
P 
Mudge 
2007166 
Crit val F n=25 chronic stroke patients, median 
age = 69 (range 42-79), 32%f 
Lab; 6 trials on a 6m walkway 
without shoes at a self-selected 
3-dimensional gait analysis  Pearson’s r=0.959 (non-paretic limb) and r=0.896 
(paretic limb) 
P 
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pace  
 
Crit val F n=21, chronic stroke patients, full 
sample median age = 69 (range 42-79), 
32%f 
Lab; indoor: 8m at self-selected 
pace and 8m at fast pace, 
outdoor: 200m course including 
steps, inclines and declines 
wearing usual footwear at a 
self-selected pace (with rest if 
required).  
On/off event footswitches 
taped to the foot 
95% LOA: non-paretic limb ±9 steps, paretic limb 
±57 steps   
Percentage error:  non-paretic limb -1.3% (range, -
4.5% to 2.5%), paretic limb -4.2% (range, -42% to 
16%).  
Pearson correlations: non-paretic limb r=0.999, 
paretic limb r=0.963 
P 
Ng 2012167 Crit val F, I 
 
N=20, chronic obstructive pulmonary 
disease patients with functional 
limitation, 73 (8.5), 60%f 
 
Lab; walking course; self-
selected slow and normal paces 
with and without a rollator for 
5min each.  
Observer (average of 30s 
interval at start of 2nd, 3rd and 
4th minute) 
Mean bias = +2 steps/min, 95% LOA 6 steps/min 
(-4 to 8 steps/min).  
No effect of rollator or walking speed on validity of 
step rate. 
P 
Resnick 
200197 
Crit val F  
 
N=30, older adults (65+) with 
Parkinson’s (n=3), previous hip fracture 
(n=10) or evidence of degenerative joint 
disease and/or osteoporosis (n=17), 86 
(6.1), 73%f 
Lab; 1min walk at self-selected 
speed over carpet, repeated 
after a 2min rest  
Mean of two observers 
(experienced nurses). Inter-
rater reliability = 0.98 
Correlations (type not stated) r=0.95 (p<0.05)  
% accuracy = 96%  
% error = 4.0±3.1% (range 0-12%) 
F 
Schmidt 
2011168 
Crit val F 
 
N=20, individuals with Parkinson's 
disease (n=11, 66.8 (SD NR)) or 
multiple sclerosis (n=9, 55.8 (SD NR)), 
Lab; walking course; 3 walks at 
usual speed over the GaitMat II  
GaitMat II Pearson correlations: Multiple sclerosis r=0.99, 
Parkinson’s disease r=1.0.  
Mean strides: 15.55 (SAM) and 15.85 (GM). 
P 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
65%f 
Shepherd 
199990 
Crit val F  n=29, healthy individuals able to 
comfortably walk a mile and two flights 
of stairs. 42.3 (15.3), 72%f 
Lab; 2 trials of: 1) brisk walking 
around a 400m track 2) slow 
walking for 10m (household 
pace) 3) ascend 11 steps, 4) 
descend 11 steps 
Single observer with handheld 
counter 
Percentage accuracy 
mean (SD) (positive=over-counting). overall = 
0.54% (0.7), 1) 0.31 (0.7) 2) 5.25% (5.7) 3) 3.58% 
(5.2), 4) 7.25% (11.6). Not affected by BMI, gender 
or lower leg surgery.  
P 
Storti 200883 Crit val F, I N=34, 65+ and able to walk 
independently without an assistive 
device, 79.2 (6), 71%f 
Lab; walking course; walked 
100 steps on level surface at 
self-selected pace  
Observer with handheld step 
counter 
Percentage error:  total +6.9, slow gait = +6.5, 
middle-speed gait = +6.6, fast gait = +2.8 (SAM 
over-counting) 
Absolute percentage error total 5.7 (5.0), slow 6.6 
(5.7), medium 6.6 (5.5), fast 3.6 (2.9) 
F  
Wendland 
201298 
Crit val F N=15, healthy adults using an assistive 
device, able to ambulate >10m without 
rest, (full sample n=16) 75.6 (SD NR), 
mixed (NR). 
Lab; walking course; 2x10m 
each over linoleum, pavement, 
grass, up and down a ramp, and 
up and down stairs. SAM 
attached to cane and right leg.  
Observer for leg strides and 
observer for cane strides with 
handheld tally counters 
Percentage accuracy: leg = 93.4%, cane = 84.7%.  
Stairs less accurate (p<0.001). 
 
P 
Busse 200985 Cons val F, D, 
I 
n=22, healthy volunteers, 26.9 (22-45), 
gender NR 
Home/community; Everyday 
activities for 4 days 
4-day activity diary (main 
activity recorded in 15-min 
blocks) and classified into 
inactive, low, moderate and 
Spearman’s for counts of 15min blocks in activity 
level  
Inactive ρ=0.47 (p<0.05), low ρ=0.42 (p<0.05), 
medium ρ=0.48 (p<0.05), high ρ=0.59 (p<0.01)  
P 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
vigorous based on METs 
Bowden 
200791101 
TRR F n=11, diagnosis of incomplete spinal 
cord injury with no more than minimal 
assistance required for walking, 45.5yrs 
(range 21-63), 18.2%f 
Lab; 1 x 6MWT at usual pace 
over series of hallways, 2 x 10m 
WTs at self-selected pace, 
completed at 2 different times 
in randomised order  
4hrs to 1 week later both tests 
repeated 
ICC (2,1) 6MWT = 0.99, 10mWT = 0.97  P 
Busse 200985 TRR F n=20, healthy volunteers, 26.15 (range 
17-38), gender NR 
Lab; 3 outdoor 20min circuit 
walks with ramps, lifts etc using 
metronome to standardise 
cadence 
Three walks of same circuit ICC=0.96 P 
Busse 200462 TRR F, D, 
I 
n=10 healthy adults, 43.3 (18.9), 40%f; 
n=10 ambulant neurological patients 
with impairments from different 
pathologies with restricted walking 
mobility but able to walk >10m without 
assistance, 59.4 (13.4), 50%f 
Home/community; Everyday 
activities for  two 7-day 
monitoring periods (SAM worn 
for 24hr/day ad removed for 
bathing) 
1-3 weeks apart Healthy step count: ICC=0.89 day to day CV=28%, 
week to week CV 8.8%. Peak activity index 
ICC=0.98. 20min sustained activity ICC=0.75. 
30min sustained activity ICC=0.71, 60min 
sustained activity = 0.57. 
Neurological patients step count ICC=0.86 day to 
day CV=30%, week to week 12%. Peak activity 
index ICC=0.82, 20min sustained activity ICC=0.94. 
30min sustained activity ICC=0.90, 60min 
sustained activity = 0.95.  
P 
Haeuber TRR F n=17, >50, remote ischaemic stroke Home/community; total strides Average per day of two 48 hr ICC=0.96 (p<0.001) P 
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2004169 over 6mth ago, residual hemiparetic 
gait defects but capacity for ambulation 
with assistive device. 65 (6), gender NR 
over 48 hours periods, up to 3 weeks' apart 
Algase 200377 TRR D Sample size not clear, individuals with 
dementia, (full sample n=178) 85.3 
(6.3), 75%f 
 
Nursing home; free-living 
wandering in 1-4 four-hour 
periods 
Time interval: 3 days Pearson’s correlations r=0.71 (p<0.001) F 
Mudge 200875 TRR F, I N=40, >6 months post-stroke, able to 
walk independently but with some 
residual difficulty, 69.2 (12.6), 43%f 
Home/community; mean steps 
in free-living three day period 
Time interval: 1 week (same 3-
day period) 
Total step count ICC = 0.989; CV = 10.7%;  
Medium rate steps:  ICC = 0.964; CV = 17.8%;  
High rate steps: ICC=0.926; CV=37.6%;  
Low rate steps:  ICC=0.953; CV=11.1% 
F 
Macko 200294 TRR F N=16, patients >55 yrs with remote 
ischemic stroke (>6 months), with 
residual hemiparetic gait deficits and 
some preserved capacity for 
ambulation, 67 (7), mixed (NR). 
Rehabilitation centre; walking 
course; 2x6min walks at self-
selected pace using their 
normal adaptive 
device/orthosis  
Time interval: >=1 day (NR) ICC r= 0.975, P < 0.0001 P 
Mudge 
2010170 
TRR F, I N=15, healthy adults, (full sample n=30) 
27.7 (8.9), 50%f  
Home/community; 3 days free-
living activity  
Time interval: 1 week (same 3-
day period) 
Mean steps/day: ICC=0.895; CV=11.8%; 
Medium rate steps: ICC=0.854; CV=13.0%; 
High rate steps: ICC=0.744; CV=36.9% 
P 
Resnick 
200197 
TRR F N=30, older adults (65+) with 
Parkinson’s (n=3), previous hip fracture 
Lab; 1min walk at self-selected 
speed over carpet, repeated 
Time interval: 2min ICC r=0.84 F 
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(n=10) or evidence of degenerative joint 
disease and/or osteoporosis (n=17), 86 
(6.1), 73%f 
after a 2min rest 
Subramony 
201272 
TRR F, D, 
I 
N=19, ambulatory (with/without an 
assistive device) individuals with 
different spinocerebellar ataxias, 56 
(10.7), 79%f 
 
Home/ community; free-living 
wear for 8 days 
Time interval: days 1-3 
compared to days 5-7 
Percentage time in activity: low speed ICC=0.872, 
moderate speed ICC=0.886, high speed ICC=0.606.  
Percentage steps: low speed ICC=0.912, moderate 
speed ICC=0.893, high speed ICC=0.793. 
Average daily step count ICC=0.900.  
Steps/min ICC=0.864. 
P 
Foster 200587 Inter-
rater rel 
F n=20, healthy adults 50% lean 30 (13), 
50% obese 32 (7), age range = 21-51yrs, 
50%f  
Lab; 15min walks at 1, 2 and 3 
mph each. Level ground 
walking at 1 and 1.85mph each 
for 25min.  
SAM worn on inside of left 
ankle and outside of right ankle 
during same trials.  
Mean bias 0.18±0.28 steps/min at 1ph, 0.18±0.31 
steps/min at 2 mph, and 0.04±0.06 steps/min at 3 
mph. Hall walking = 0.02 steps/min compared to 
treadmill measures 
P 
Bowden 
2007101 
ME F n=11, diagnosis of incomplete spinal 
cord injury with no more than minimal 
assistance required for walking, range 
21-63, 18.2%f 
Lab; 1 x 6 minute walk test at 
usual pace over series of 
hallways, 2 x 10minute walk 
test at self-selected pace, 
completed at 2 different times 
in randomised order (4 hrs - 1 
week later) 
4hrs to 1 week later both tests 
repeated 
Standard error of measurement  
6 minute walk test = 6.0 steps 
10 minute walk test = 0.76 steps 
P 
Mudge 200875  ME F, I N=40, >6 months post-stroke, able to Home/community; free-living Time interval: 1 week (same 3- 95% LOA (absolute,%):  F 
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 walk independently but with some 
residual difficulty, 69.2 (12.6), 43%f 
mean steps over 3 days;  day period) Total 3 day step count = ±1801 (37.8)  
Medium rate steps = ±836 (87.1%)  
High rate steps = ±1750 (153%) 
Low rate steps =±1643 (63.6%) 
Mudge 
2010170 
ME F, I N=15, healthy adults, (full sample n=30) 
27.7 (8.9), 50%f  
Home/community; 3 days free-
living activity  
Time interval: 1 week (same 3-
day period) 
95% LOA (absolute, %) 
Mean steps/day: 3341 (39.1%) 
Medium rate steps: 2111 (53.5%) 
High rate steps: 2521 (122%) 
P 
Ng 2012167 Resp to 
change 
F, I N=20, chronic obstructive pulmonary 
disease patients with functional 
limitation, 73 (8.5), 60%f 
Lab; walking course; self-
selected slow and normal paces 
with and without a rollator for 
5min each 
Step rate at slow and normal 
paces and with/out rollator 
(speed regulated by audio 
signals) 
ANOVA: significant effect of walking speed (F1,19 = 
88.69; p < 0.01) on step rate as measured by SAM. 
Significant effect of rollator (F1,19=12.39, p=0.02). 
No interactions between speed and rollator.  
P 
StepWatch Activity Monitor acceptability studies (n=24) 
Algase 200377 Acc D, O n=72, ambulatory nursing home 
residents with dementia, full sample 
(n=178) 85.3 (6.31), 75.3% 
Wandering activity for 4x4hr 
periods  
Wear rates 29.2% wore SAM for all 4 periods. 83.3% accepted 
a device for any period. MMSE and age did not 
predict device acceptance. N=288 periods: 57.98% 
periods had available data, 0.69% periods had 
equipment failure, 0% project/staff problems, 
1.48% setting issues, 28.80% subject issues, other 
= 11.0% . SAM was added later in study 
- 
Algase 200377 Acc D, O n=17, nursing home staff, age NR, Patients with dementia wearing Rating scale 0-5 scale (unacceptable to highly acceptable): - 
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gender NR SAM for 4x4hr period Appearance: 3.50 (0.76), Comfort: 3.47 (0.80), 
Concealment: 3.74 (0.61), Easy application: 3.19 
(0.98), Ease of cleaning: 3.25 (0.92), Location: 3.76 
(0.55), Safety: 3.71 (0.59), Size: 3.53 (0.79), 
Weight 3.76 (0.49). Rated second most highly on 
six scores out of four devices 
Barak 2014171 Acc F n=408, >18, 5-30 days after stroke 
without contraindications to exercise, 
62.02 (12.74), 45.1%f 
Everyday activities for 2 days, 
removed for bathing, 
showering, swimming or 
sleeping 
Wear time Inferred adherence per day = activity (>2 steps) 
within each six hour time period (6am-12pm, 12-6 
and 6-12am) for each day. Day 1 = 68.1% 
adherence, Day 2 = 60.8%, Both = 52.9%, Either 
day = 76.0%. Logistic regression indicated that 
older individuals with better balance self-efficacy 
and walking endurance were more likely to 
adhere to the SAM protocol. Written information 
and reminders given.  
- 
Bergman 
200581 
Acc F n=37, >65 living in independent living 
(n=17), assisted living (n=8) and 
nursing home facilities (n=12) in 
Knoxville, 85.81 (4.16), 70.3%f 
Everyday activities for 1 full 
weekday, removed only for 
bathing  
Wear time Average wear time = 13.66 (1.26) hours. 
Retirement homes (n=17) = 12.63 (1.43) Assisted 
living (n=8) = 13.82 (1.26) Nursing home (n=12) = 
14.13 (0.84). Reminders and instructions were 
provided to participants and staff. 
- 
Busse 200462 Acc F, D, n=10 healthy adults, 43.3 (18.9), 40%f; Everyday activity for two 7-day Wear rates "All subjects were compliant in continuous - 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
I n=10 ambulant neurological patients 
with impairments from different 
pathologies and restricted walking 
mobility 59.4 (13.4), 50%f.  
periods. SAM worn for 
24hr/day 
wearing of the monitor throughout the monitoring 
period. This was confirmed by visual inspection of 
the data" (No clear definition of non-compliance 
or visual inspection) 
Cavanaugh 
201163 
Acc F, D, 
I 
n=21, ambulatory, community-dwelling, 
multiple sclerosis patients, 57.6 (12.7), 
57.1%f 
Everyday activities for 7 days 
(waking hours only except 
bathing, sleeping or swimming) 
Wear rates 19 (90%) completed >=6 days of recording. Range 
= 3-7 days 
- 
Cavanaugh 
201278 
Acc F, D, 
I 
n=57, Parkinson's disease patients. Of 
33 complete data 67.06 (8.75), 33.3%f 
All activity for 7 days, except 
bathing, swimming or 
showering, worn on least 
affected leg. SAM worn at 
baseline and 12 month follow-
up 
Wear rates 57 wore monitors at baseline, 37 at following year. 
Data recording problems (incorrect wear and 
computer docking issues) = 4 (10.8%). Mean (SD) 
days of wear = 6.7 (1.1) at baseline (n=57), 6.4 
(1.0) at 1 year (n=33).  In a few cases, participants 
decided to wear the monitor 1-2 additional days. 
In a few cases, activity data from a day were 
excluded due to minimal activity compared to all 
other days 
- 
Danks 201464 Acc F, D, 
I 
n=23, stroke survivors  (>6 months post 
stroke), walking without assistance 
(devices allowed), n=16 completers, 66 
(range 40-78), 19%f 
SAM on non-paretic leg, worn 
for all waking hours (except 
bathing and swimming) for 4 
weeks 
Wear rates 2/23 (8.7%) withdrew due to difficulty attaching 
the SAM or consistently wearing it. 2/19 (10.5%) 
did not return SAM with minimum 3 full 
days/week captured activity as per protocol and 
one admitted to inflating her baseline step activity. 
- 
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2 withdrew for reasons unrelated to study 
Franklin 
200665 
Acc F, I n=8, primary total knee arthroplasty 
patients with varying characteristics, 
age and gender NR 
6 knee exercises during week 3-
12 after surgery. SAM worn for 
4 continuous days before 
surgery and during 
postoperative week 6.  
Wear rates All patients successfully wore the SAM before and 
after surgery. No complaints or problems. SAM 
returned by post 
- 
Gundle 201479 Acc F n=29, lower extremity sarcoma 
(primary or recurrent) patients treated 
with limb salvage, 55yrs (range 22-76), 
62%f 
Everyday activities for 7 days 
(waking hours only except 
bathing, sleeping or swimming) 
Wear rates Patients wearing SAM upside down, incorrectly 
positing or non-wear for >3hr a day were excluded 
to give n=29. Mean days of data collection in 
included patients = 12 (3), range 6-16. Non-wear 
was not defined and n excluded not reported.  
- 
Hiatt 201148 Acc F, D, 
I 
n=69 randomised, 62 analysed; 
intermittent claudication >=1 yr, 67 (SD 
NR), 37.8%f 
Home-based walking exercise 
2-3 times per week initially for 
30-50min per session; everyday 
activities for >=10hr/day for 
seven days at screening, 3 mo 
and 6 mo  
Wear rates Baseline: 83.5% recorded >10hr ambulatory 
activity (unclear how detected), 6mo 63% 
recorded >10hr, 3mo NR  
 
Kong 201466 Acc F, D, 
I 
n=46 (37 completed), inactive obese or 
overweight pregnant women, 26.95 (SD 
NR), 100%f 
Walking programme, increasing 
from 50-150min/week or no 
intervention. SAM worn for 4 x 
1 week periods 
Wear rates >3 days of valid data: timepoint 1 n=31/37 (84%), 
timepoint 2 n=36/37 (97%), timepoint 3 n=35/37 
(95%), timepoint 4 n=35/37 (95%). Exclusions 
were mainly due to missing data and SAM 
- 
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misplacement. Mean=6 days for each timepoint 
per ppt. No difference in compliance between 
intervention or control. 
Moy 2014a172, 
Moy 2014b173, 
Danilack 
2014174 
Acc F n=173, chronic obstructive pulmonary 
disease patients, >40yrs, stable clinical 
condition, 71 (8), 1.2%f 
Everyday activities for 14 days Wear rates 5/173 (2.9%) had >=8 no-wear days (defined as 
<200 steps and <8hrs wear time). 81/2338 days 
(3.5%, 167x14) met no-wear criteria in final 
sample. 98 participants wore the monitor twice - 
122/3766 days (3%) were no-wear days.. 
Subsample in separate study had 48/1428 (3%) 
no-wear days. Unclear how many participants 
wore the SAM for the entire 14 days 
- 
Mudge 200875 Acc F, I n=54, >6mo post-stroke, able to walk 
independently but with some residual 
difficulty, completers (n=40) 69.2 (12.6) 
, 40%f 
Everyday activities for 3 days 
one week and same 3 days 
following week, removing for 
sleeping and showering.  
Wear rates 13/54 (24.1%) did not wear SAM for six full days. 
40/54 (74.1%) had full six days, n=1 withdrew. 
Written instructions were provided for SAM. 
- 
Mudge 200968 Acc F, I n=50, >6mo post-stroke, able to walk 
independently but with some residual 
difficulty, 67.4 (12.5), 40.8%f 
Everyday activities for 3 days, 
SAM attached to non-paretic leg 
Wear rates 49/50 (98%) had 3 complete days of data (not 
defined) 
- 
Mudge 
2010170 
Acc F, I n=30, healthy adults, 27.7 (8.9), 50%f Everyday activities for 3 days 
one week and same 3 days 
following week, removing for 
Wear rates 2 x 3 days = 50%, 2x 2 days = 50%. High attrition. 
Written instructions were provided for SAM. No 
significant differences between completers and 
- 
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sleeping and showering.  non-completers 
Nguyen 
201169 
Acc F, D, 
I 
n=17, COPD patients who had 
completed pulmonary rehabilitation, 68 
(11), 64.7%f 
Everyday activity (waking 
hours only) for 14 days at 
baseline, 3 mo and 6mo (42 
days total) 
Wear rates 564 person-days of free-living ambulatory activity 
were recorded. 33.2 (9.9) valid days (>=10hrs of 
monitor wear) per person. Mean = 13.9 (0.3) 
waking hours recorded. 39% had 14 days at each 
timepoint. 89% had 11 days for each timepoint.  
- 
Nguyen 
201169 
Acc F, D, 
I 
n=60 healthy older adults aged 60-
80yrs, 70 (6), 51.7%f 
Everyday activity for 7 days Wear time Average monitoring days per person = 7.0 (1.5), 
442 person days total 
- 
Nguyen 
201380 
Acc F n=148, chronic obstructive pulmonary 
disease patients, 66,5 (8.8), 22%f 
Everyday activities for 7 days 
(waking hours only) 
Wear time Median wear time = 7 days. Valid day >=10hr 
(600min) monitor wear. High anxiety symptoms 
mean = 874 mins/day wear, low anxiety 
symptoms mean = 899min/day wear (p=0.29) 
- 
Parker 201070 Acc F, D, 
I 
n=27, >18, lower limb prosthesis for 
>1yr. Full sample (n=52, SAM 
subsample) were age 55.2 (15.8), 
21.2%f.  
Everyday activities for 7 days Wear time Non-wear (not defined): 4 days = 2 participants 
(7.4%), 6 days = 3 participants (11.1%)  
- 
Roos 201271 Acc F, D, 
I 
n=54 stroke survivors able to walk 
without assistance from another person, 
63.7 (10.4), gender NR; n=18 retired or 
semi-retired older adults living in the 
community without walking deficits, 
Everyday activity for 3 days 
(waking hours only except 
bathing and swimming) 
Wear rates 7/72 (9.7%) did not have 3 days of ambulation 
activity (3/54 (5.6%)  stroke survivors, 4/18 
(22.2%) older adults) 
- 
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68.9 (6.2), gender NR 
Subramony 
201272 
Acc F, D, 
I 
n=19, ambulatory individuals with 
different spinocerebellar ataxias, 56 
(10.66), 78.9%f 
Everyday activities for 7 x 24hr 
periods (8 days), day and night 
Wear rates "patients...wore it faithfully through all activities 
with no interruptions in the recordings."   
- 
Varma 201473 Acc F, D, 
I 
n=195, >=60yrs, 66.8 (5.6), 76.5%f. 
Obesity (8.3%), hypertension (71.2%), 
osteoarthritis (61.8%) and diabetes 
(32.6%) fairly prevalent.  
Everyday activity for 3-7 days Wear time Average data = 4.9 days. Average of 0.8 days 
(16.4%) removed from analysis. 8/195 non-
compliant (defined as a) <201 total steps/day, b) 
days with <6hr of any activity between wake and 
sleep c) days with 6hr of consecutive inactivity (<1 
step) between wake and sleep and d) subjects self-
reported in diary that they hadn't complied). Final 
187 participants provided 4.3 days' data (range 1-
9) each.  Unclear how this subset were chosen 
from larger RCT. Vague number of days’ wear 
prescribed.  
- 
White 2012175 Acc F n=1343, community dwelling adults 
>50 with a previous knee injury or 
operation, body weight >median value 
for age and sex-specific group, knee OA 
confirmed radiographically,   63.1 (7.8), 
60%f 
Daily walking for 7 days, 
waking hours only 
Wear rates Out 1343 eligible participants, 1116 (83%) 
received a SAM and 1018 (93%) wore it for 3+ 
days. Of the 229 who did not receive a SAM, 72% 
refused, 16% had impairments preventing use, 7% 
had no device available to them, and 5% had other 
reasons. Unclear why high refusal rate or why no 
- 
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devices were available for some. Times were 
omitted when no steps for >180mins 
consecutively. 
Problematic Experiences of Therapy Scale high quality studies (n=4) 
Kirby 
2014103 
Int cons Gen n=128, patients with chronic 
dizziness, original sample (n=170) 
G1 63.9yrs (15.2), 71%f, G2 61.0yrs 
(14.4), 71%f 
Home; up to 12 weeks’ 
dizziness rehabilitation 
exercises. PETS completed 
at 12 weeks post-treatment 
assessment. 
Subscale items Symptoms: α=0.91 
Uncertainty: α=0.96 
Doubts about efficacy: α=0.94 
Practical problems: α=0.84 
E 
 Int cons Gen n=225, Meniere’s disease patients 
with dizziness symptoms, original 
sample (n=227) G1: 58.0yrs (11.4), 
73%f, G2: 60.0yrs (13.6), 63%f 
Home; up to 12 weeks’ 
dizziness rehabilitation 
exercises. PETS completed 
at 12 weeks post-treatment 
assessment.  
Subscale items Symptoms: α=0.91 
Uncertainty: α=0.93 
Doubts about efficacy: α=0.84 
Practical problems: α=0.87 
E 
 Struct 
val 
Gen n=128, patients with chronic 
dizziness (labyrinthine cause), 
original sample (n=170) G1 
63.93yrs (15.21), 71%F, G2 
61.01yrs (14.42), 71%F 
Home; up to 12 weeks’ 
dizziness rehabilitation 
exercises. PETS completed 
at 12 weeks post-treatment 
assessment.  
Scale items PCA: Four factor solution corresponding to 4 
hypothesised subscales, accounting for 84% 
of the variance. All items loaded onto one 
factor for >=0.67 and <0.10 on others. All 
factor eigenvalues >0.9. Subscale 
E 
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correlations range from -0.22 to -0.53.  
 Struct 
val 
Gen n=225, Meniere’s disease patients 
with dizziness symptoms, original 
sample (n=227) G1: 58.0yrs (11.4), 
72.5%f, G2: 60.0yrs (13.6), 62.5%f 
Home; up to 12 weeks’ 
dizziness rehabilitation 
exercises. PETS completed 
at 12 weeks post-treatment 
assessment.  
Scale items PCA: Four factor solution corresponding to 
the 4 hypothesised subscales, accounting for 
81% of the variance. All factor loadings 
>=0.60 and <0.11 on other factors. All factor 
eigenvalues >1. Subscale correlations ranged 
from 0.12 to 0.36.  
E 
Problematic Experiences of Therapy Scale low quality studies (n=3) 
Yardley 
200611 
Crit val Gen N=223, Meniere disease, dizziness or 
imbalance symptoms over 12 months, 
VR group (full sample n=120) 58 (11.4), 
73%f, SC group (full sample n=120) 
60.0 (13.6), 62.5%f  
Home/ community; vestibular 
rehabilitation or symptom 
control 3 months  
Self-reported adherence for 9-
12 weeks or until 
asymptomatic (2 questions) 
T-test: PETS subscales scores significantly higher 
in non-adherent group (all p<0.01) 
 
P 
Kirby 2014103 Cons val Gen n=128, patients with chronic dizziness 
(labyrinthine cause), original sample 
(n=170) G1 n=83 63.93 (15.21), 71%F, 
g (N=87) 61.01 (14.42), 71%F 
Up to 12 weeks' dizziness 
rehabilitation exercises. PETS 
completed at 12 weeks post-
treatment assessment and 
coded into "no barriers" or 
"some barriers" for each 
subscale.  
12 weeks: Participant self-
report adhering for >9 weeks or 
until asymptomatic 
Chi-squared between low adherers. Symptoms: 
some barriers 47%, no barriers 14.6% (p<0.001). 
Uncertainty: some barriers 51%, no barriers 
26.4% (p<0.01). Doubts: some barriers 50%, no 
barriers 20% (p<0.001). Practical problems: some 
barriers 42.9%, no barriers 25% (p<0.05).  
P 
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Kirby 2014103 Cons val Gen n=227, Meniere's disease patients with 
dizziness symptoms in the last 12mo, 
Original sample G1: n=120 58.0 (11.4), 
72.5%f, G2: n=120 60.0 (13.6), 62.5%f 
Up to 12 weeks' dizziness 
rehabilitation exercises. PETS 
completed at 12 weeks post-
treatment assessment and 
coded into "no barriers" or 
"some barriers" for each 
subscale.  
6 mo: self-report adhering after 
12 weeks (any duration) 
Chi-squared for maintenance. Symptoms: no 
barriers 47.5% (p<0.01), doubts 47.5% (p<0.01).  
P 
Problematic Experiences of Therapy Scale acceptability studies (n=1) 
Yardley 
200611 
 G n=240 (2 intervention groups), 
individuals with Meniere's disease 
experiencing dizziness or imbalance in 
last 12 mo; VR group=58.0 (11.4), 
72.5%f; SC group= 60.0 (13.6), 62.5%f 
Home-based booklet vestibular 
rehabilitation (VR; daily 
balance training exercises and 
how to tailor to symptoms) or 
symptom control (SC; 
relaxation and breathing 
exercises) for 3 mo 
Return rates 225/240 (93.8%) completed PETS at 3mo. No 
information on individual item rates. PETS was 
packaged with other questionnaires.  
- 
Adherence diaries high quality studies (n=6) 
Wilbur 
2001106 
 
Crit val F, D n=156, sedentary African American and 
Caucasian women, mean (SD) age NR 
(range 45-65yrs), 100%f  
Home/community; moderate 
intensity 24-week walking 
program.  
Polar Vantage XL heart rate 
monitors  
Frequency = +4.33 (SD 7.09) walks on log 
(r=0.962, p<0.01), duration = +5.0 (SD 8.08) min 
on monitor (r=0.536, p<0.001) 
E 
Crit val F, D n=139, sedentary African American and 
Caucasian women, mean (SD) age NR 
Home/community; moderate 
intensity 24-week walking 
Change in fitness (VO2max in a 
treadmill test) between 
Frequency of walks and change in VO2max = 0.270 
(p<0.01); average duration and change in VO2max = 
G 
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(range 45-65yrs), 100%f  program.  baseline and post-intervention.   -0.088 (NS). Similar correlations found between 
monitor variables and change in VO2max.  
Jeffrey 
2012107 
Crit val F n=135, adults over 60 with osteopenia 
of the hip or spine, age 82.3yrs (7.1), 
67%f 
Home/community; use of active 
or sham vibrating platform for 
10min per day for up to 3yrs 
Radio frequency identification 
card system  
Mean bias close 0.02 and narrow LOA (graph 
only), ICC=0.96 
G 
Lindseth 
2005104 
Crit val D n=94, women within the first 12 weeks 
of pregnancy, 27yrs (4.6), 100%f 
Home/community; exercise for 
3 days at 14 and 28 weeks’ 
gestation 
Mean Accu-split Power Stride 
pedometer counts per day  
r=0.49 (p<0.02) G 
Shang 2009105 Crit val F, D, 
I 
n=126, newly diagnosed cancer 
patients, 60.2yrs (10.6), 61%f 
Home/community; walking 
programme 5 days per week for 
5-35 weeks 
Pedometer steps (brand NR) 
worn for whole study 
(intervention) or first and last 
two weeks of study (control) 
ρ=0.42 (p<0.001) G 
Cons val F, D, 
I 
n=126, newly diagnosed cancer 
patients, 60.2yrs (10.6), 61%f 
Home/community; walking 
programme 5 days per week for 
5-35 weeks 
Physical Activity Questionnaire 
METs of previous 4 weeks 
(administered at end of study) 
ρ=0.67 (p<0.001) 
 
G 
Adherence diary low quality studies (n=30) 
Castro 
2002111 
Crit val F, D, 
O 
n=9, sedentary and healthy post-
menopausal women providing unpaid 
care to a relative with dementia, total 
sample (n=51) 62.2 (9.3), 100%f 
Hone; exercise programme of 
increasing intensity - 4x 30-
40mins per week for 12 mo.  
Solid-state two-channel 
portable microprocessor  
recording heart and body 
movement for one 3 day period 
87.5% agreement between continuous bouts of 
physical activity at moderate intensity heart rate 
as recorded by the monitor and logs.  
P 
Dougherty Crit val D n=77, single or dual chamber Home; 8 week home-based Fitness (peak VO2 measured by Test unclear, participants achieving >=80% F 
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2015123 Implantable Cardioverter Defibrillator 
patients taking beta-blockers and 
willing to complete the exercise 
program, of n=84 at start 56.1(12.1), 
20.2%f 
aerobic training followed by 16 
week maintenance with 
increases in heart rate targets  
CPET using symptom-limited 
treadmill test) 
adherence during aerobic conditioning achieved 
significantly higher peak VO2 (27.7 (7.0) vs 24.3 
(6.7), p=0.03) and associated exercise outcomes 
(data NR) 
Franklin 
200665 
Crit val F n=8, total knee arthroplasty  patients, 
total sample (n=21) 69 (SD NR), 67%f 
Home; daily leg exercises for 9 
weeks 
SAM-recorded periods of 
sustained step activity for 4 
days during week 6 
All diary-reported exercise sets were recorded as 
high activity peaks on the SAM, plus extra 
P 
Crit val F, O n=21, total knee arthroplasty  patients, 
69 (SD NR), 67%f 
Home; daily leg exercises for 9 
weeks 
Physical composite score of SF-
12  
Regression: daily repeats in leg exercise and PCS 
changes: slope = 0.34 (p=0.10), knee reflex repeats 
and PCS changes: slope = 0.31 (p=0.09) 
P 
Jakicic 
1998118 
Crit val F, D N=50, overweight women, mean & SD 
NR (range 25-50), 100%f 
Home/ community; part of 20 
week trial comparing long 
(1x20-40min per day) and 
short (2-4x10min per day) 
bouts of exercise  
 
 
Tri-Trac accelerometers (6 days 
between randomly allocated 
between weeks 5 and 10) 
29 (58%) under/accurately reported session 
frequency, mean difference -1.5±2.4 sessions, 
88.5±24.2% sessions matched 
21 (42%) over-reported, mean difference 2.9±2.3 
sessions, 44.0±28.1% sessions matched 
26 (52%) under/accurately reported mins per 
week: mean difference in duration -42.8±45.5 
mins 
24 (48%) over-reported: mean difference in 
duration 71.5±78.4 mins 
P 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
Lyngcoln 
2005176 
Crit val F 
 
n=15, individuals =<18 with a distal 
radial fracture managed conservatively 
in a cast, 65.1 (11.1), 93%f 
Home; home-based hand 
therapy exercises for six weeks 
Functional status scale 
(modified Levine 
questionnaire) 
Pearson's r=0.63 (p<0.05) P 
Jebsen test of hand function  Spearman's Item 1: ρ=0.40, item 2: ρ=0.51, item 3: 
ρ=0.25, item 4: ρ=0.26, item 5: ρ=0.54 (p<0.05), 
item 6: ρ=0.39, item 7: ρ=0.32 
P 
Active wrist extension Pearson's r=0.46 P 
Hand dynamometer (grip 
strength) 
Pearson's r=0.41 P 
Pain (VAS) Pearson's r=0.54 (p<0.05) P 
all of the above Pearson's r=0.44 
Number of exercises performed and all outcome 
measures r =0.29 
P 
McAuley 
1991125 
Crit val F, D n=48, sedentary healthy female 
university employees, 39 (SD NR), 
100%f 
Home/community; twice 
weekly supervised 1hr exercise 
classes for eight weeks, plus 
home aerobic exercise of 
>15min 
Body weight (calibrated 
balance) 
MANOVA by participants >median overall 
adherence: p<0.1 
P 
Body fat  (three site method of 
skinfold thickness) 
MANOVA by participants >median overall 
adherence: NS 
P 
Moseley 
2006120 
Crit val F N=51, complex regional pain syndrome 
type 1 of one limb diagnosis from their 
treating practitioner, full sample n=67: 
Home; RCT of overt vs covert 
adherence monitoring of 
computer-based motor imagery 
In-house software recording 
performance time and duration. 
Overt monitoring (n=24): 5% (95% CI 0.51–9.48) 
underestimation.  
Covert monitoring (n=27): 10% (95% CI 3.0–16.9) 
P 
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32 (10), 48%f home exercise programme  overestimation. 
Longer symptom duration correlated with greater 
inaccuracy.   
Sassi-
Dambron  
1994177 
Crit val F, D n=42, patients with chronic obstructive 
pulmonary disease, 61.4 (7.6), 24%f 
Home/community; initially 3 
short walks increasing to one 
long walk up to a goal of at >30 
min per day for 8 weeks 
Maximum exercise tolerance 
(Maximum METs, symptom-
limited treadmill test collecting 
blood gases) 
Pearson’s: Total minutes walked r=0.32 (p<0.05), 
total days walked r=0.05 
 
F 
Maximum exercise tolerance 
(peak VO2, symptom-limited 
treadmill test collecting blood 
gases) 
Total minutes walked r=0.18, total days walked 
r=0.05 
F 
Endurance time (constant work 
treadmill test) 
Total minutes walked r=0.37 (p<0.05), total days 
walked r=0.22 
F 
Shaw 2005119 Crit val D n=4, chronic traumatic brain injury >1 
yr prior to participation with relative 
hemiparesis, full sample (n=22) 39.3 
(14.4), 35%f 
Home; constraint-induced 
movement therapy (mitt wear) 
and other behavioural 
techniques for 2 weeks 
Sensor and timing device sewn 
into mitt 
Median ICC = 0.97 P 
Crit val F, D n=22, chronic traumatic brain injury >1 
yr prior to participation with relative 
hemiparesis, 39.3 (14.4), 35%f 
Home; constraint-induced 
movement therapy (mitt wear) 
and other behavioural 
techniques for 2 weeks 
Motor Activity Log  Quality of 
Movement 
T-test adherent (>57%) vs non-adherent = 1.8 vs 
1.3 (p=0.065), correlation in less adherent 
participants r = 0.68, none among more adherent 
participants  
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Wilcox 
2004178 
Crit val F, D n=18, >=65yrs, no cardiovascular 
disease, stroke or musculoskeletal 
problems, active =<2 twice a week, full 
sample (n=103) 70.2 (4.1), 65%f 
Home; either Fit & Firm - brisk 
walking and weights or 
resistance bands or Stretch & 
Flex - home stretches twice per 
week, both 12 mo 
Solid-state portable 
microprocessor (Vitalog Corp) 
recording heart and body 
movement for 3 days 
10/12 (83%) in Fit & Firm condition showed 
evidence of an exercise bout of >=20min on days 
they reported engaging in a home exercise session. 
Only 1/6 in Stretch & Flex condition.  
P 
Yuen 2013122 Crit val F, D N=11, sedentary African-American 
women with systemic lupus 
erythematosus experiencing fatigue, 
48.8 (14), 100%f 
Home; WiiFit exercises for 
30min, 3 times a week for 10wk  
WiiFit records Mean difference (95% LOA) session duration: 
3.8min (35 to -27 mins), 12.7% difference. 
ICC=0.40 (95% CI 0.27-0.51). 72% sessions 
matched between methods. 
P 
Aurilio 
2000126 
Cons val F, D, 
O 
n=30, sedentary healthy women aged 
30-50yrs, 41 (6.3) 100%f 
Home/community; 12 week 
walking programme 
Behavioral Risk Factor 
Surveillance System Exercise 
questionnaire (telephone 
interview) 
Days walked per week ICC= 0.77 (p=0.01), 
Spearman’s ρ=0.62 (p<0.01) 
Mins walked per week ICC=0.08 (p=0.34), ρ=0.54 
(p<0.01)  
Miles walked per week ICC= 0.04 (P=0.43), ρ=0.63 
(p<0.01) 
F 
Henry 1999179 Cons val F N=15, healthy adults over 65, 72.8 (SD 
NR, range 67-82), 73%f 
Home; 2, 5 or 8 general 
strengthening exercises 10 
times a day  
Performance accuracy 
assessment tool developed for 
study (scored by PTs), inter-
rater reliability 0.87 for first 
exercise and 0.93 for second 
Correlations: r=0.54 P 
Khalil 2012180 Cons val F n=15, mid-stage Huntingdon's disease Home; PT-prescribed exercises Intrinsic Motivation Inventory Spearman's correlations P 
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with difficulties with walking or balance 
and stable medical regimen, 53.6 (range 
25-78), 47%f 
on a DVD at least 3 times/week 
for 8 weeks 
(multidimensional 
questionnaire about perceived 
interest, enjoyment, 
competence, effort, value and 
usefulness while performing a 
given activity) 
Subscales: Interest/enjoyment: 0.09, perceived 
competence: 0.39, effort/importance: 0.37, 
pressure/tension -0.63 (p<0.05), 
value/usefulness: -0.24 
McAuley 
1991125 
Cons val F, D n=48, sedentary healthy female 
university employees, 39 (SD NR), 
100%f 
Home/community; twice 
weekly supervised 1hr exercise 
classes for eight weeks, plus 
home aerobic exercise of 
>15min 
Self-motivation (self-motivation 
inventory) 
MANOVA by participants >median overall 
adherence: NS 
F 
Self-efficacy (questionnaire of 
barriers) 
MANOVA by participants >median overall 
adherence:  F (3.43) = 3.37, p<0.05 
F 
Post-program perceptions (self-
developed questionnaire of 
program success, goal 
achievement, improvements in 
conditioning and class 
enjoyment) 
MANOVA by participants >median overall 
adherence: NS 
P 
Wilbur 
2005181 
Cons val F, D n=72, sedentary healthy, employed 
Black and White women 45-65, full 
sample (n=90) 49.9 (4.8), 100%f 
Home/community; home-based 
moderately intense walking 
programme 4 times per week in 
a target heart rate range, 
progressing from 20 to 30 min 
Exercise recorded by AD in 
maintenance phase  
Multiple regression: in a model of exercise self-
efficacy, physiological measures, background 
characteristics and adherence during intervention 
phase, adherence during intervention (p<0.01) 
and self-efficacy (p=0.02) were significant 
F 
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Activity Comparator Statistic and outcome Qual 
over 24 weeks, followed by 24 
weeks maintenance stage 
predictors of walking during maintenance (40% 
variance explained overall) 
Steele 2008130 Resp to 
change 
D  n=106, adults >45 with chronic lung 
disease and shortness of breath  with 
diminished functioning due to a 
pulmonary problem who completed 
pulmonary rehabilitation, 67 (SD NR), 
8%f 
Home/community; adherence 
to exercise after pulmonary 
rehabilitation 
Exercise adherence 
intervention with weekly phone 
calls, 1 home visit, pedometer 
and exercise handbook.  
T-test self-reported minutes of activity increased 
in adherence intervention group short term: 
intervention group 3(39), control -13 (26) 
(p=0.015). Long term: intervention 1(45), control -
8 (31) (p=0.335) 
F 
Lindseth 
2005104 
TRR D N=94, women within the first 12 weeks 
of pregnancy, 27 (4.6), 100%f 
Home/community; activity 
recorded for three days at 14 
and 28 weeks’ gestation 
Time interval: 14 weeks Pearson’s correlations: r=0.61 (p<0.01) F 
Adherence diaries acceptability studies (n=19) 
Ada 200314 Acc U n=14 (control group), stroke survivors 
6mo-5yrs previously, 66 (11), 28.6%f 
Home exercise programme 
(strength, balance, 
coordination) 3 times per week 
for 4 weeks 
Return rate Return rate = 8/14 (57.1%)  Two subjects had lost 
their logs and 1 subject was lost to follow-up. Logs 
returned independently of sessions 
-  
Bauldoff 
2001113 
Acc F, D n=408, >18, 5-30 days after stroke 
without contraindications to exercise, 
62.02 (12.74), 45.1%f 
Home-based 8 week walking 
programme with or without 
music, , 2-5 days per week for 
>20mins 
Return rates 100% complied with log recording. Logs were 
returned every 4 weeks at appointments. 
pedometer-recorded distance walked also 
recorded (also completed by all) 
- 
Bodrie Acc F, D, n=40, discharged from phase II cardiac 12 weeks home-based Return rates Mailed exercise logs to the investigator every 2 - 
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1999112 I, O rehabilitation, aged >=45 (male) or 55 
(female), prior or current coronary 
heart disease and risk factors, 69 (11), 
33.3%f 
prescribed cardiac 
rehabilitation exercise 
programme 
weeks. n=3 (15%) stopped mailing log and so 
ended study. 7 others dropped out for other 
reasons. Up to 3 telephone and mail reminders per 
diary: additional calls or letters required: 0: n=19, 
1: n=4, 2: n=4, 3: n=3  
Castro 
2002111 
Acc F, D, 
I, O 
n=51 (exercise group), sedentary and 
healthy post-menopausal women >=50 
living with and providing unpaid care to 
a relative with dementia; 62.16 (9.33), 
100%f 
Exercise programme of 
increasing intensity  - 4x 30-
40mins per week for 12 mo 
Return rates Mean return rate = 8.81/12 (SD 4.39). Returned 
monthly by mail, with phone contacts to obtain 
info if not returned 
- 
Dyson 1997182 Acc D, O n=93 , participants with increased 
fasting plasma glucose (range of 5.5 to 
7.7 mmol * L -1 on two consecutive tests 
2 weeks) and >=1 risk factor for 
diabetes, Full sample (n=227) 50 (9), 
59%f 
20-30mins exercise 2-3 times 
per week, increasing to 5-6 
times per week over 12mo 
Return rates Return rate: 51/93 (55%) returned 3/4 diaries, 15 
(16%) returned none. Diaries were collected at 
each 3mo visit, unclear how many returned diaries 
in control group 
 
 
- 
Franklin 
200665 
Acc F n=31, primary total knee arthroplasty 
patients, 69yrs (SD NR), %f NR 
6 knee exercises during weeks 
3-12 post-TKA  
Completion rates 3/31 (10%) returned blank logs. 21 remaining 
participants recorded >=3 days exercise per week. 
Log completion consistent over weeks 3-12. 
Weekly collection by study coordinator, high 
attrition (n=7).  
- 
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Frost 2004183 Acc F, D, 
O 
n=26, 55-75yrs, OA or degenerative 
joint disease of the hip diagnosis, 
unilateral total arthroplasty and 
completion a course of outpatient or 
home-based physical therapy, 
experimental 66.2 (5.2), 84.6%f; control 
65.9 (6.8), 63.5%f 
Specialized Motivational 
Exercise Counselling 
intervention or to a control 
group that received usual care 
recorded for 2 months in diary 
Return rates 1 participant did not return diaries at weeks 7 and 
8 due to a life-threatening injury to a family 
member. 1 participant did not return diaries for 
weeks 5-8 as they developed a pressure ulcer on 
their heel.  
- 
Koumantakis 
200521 
Acc F n=45, low back pain, SEE group: n=29, 
39.2 (11.4) %f NR, GE group: n=26, 35.2 
(9.7), %f NR 
General exercise with (SEE) or 
without (GE) trunk muscle 
stabilisation exercises for up to 
30mins three times per week 
for 8 weeks   
Completion rates 35/45 (77.8%) completed a diary (not defined) - 
Long 200424 Acc F n=312, low back pain patients, n=206 
completing study 42.2 (SD NR), 45%f 
Lumbar exercises (three 
different types) for 2 weeks 
Return rates 68% (137/201) returned diaries - 
Loudon 
1999115 
Acc F, D, 
I, O 
n=12 (completed trial), adults with 
mildly active or remitted Crohn's 
disease not involved in any exercise in 
the previous year, 38.3(7.5), 83.3%f 
Three sessions per week of 
structured walking, either 
indoor as a group or 
individually, progressing from 
20 to 35 mins per session and 
increasing distance and 
intensity over 12 weeks 
Completion rates "all logbooks were kept in order and were found 
to be well documented after the 12 week program. 
All data in the logbooks were complete for all 12 
subjects." Logbooks were reviewed weekly by one 
investigator, including those who missed group 
sessions 
- 
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Martinez-
Silvestrini 
200525 
Acc F n=94 (three groups), chronic (>3mo) 
lateral elbow pain,  45.5 (7.7), 46.8%f 
Stretching, concentric or 
eccentric exercises (3x10 sets 
per day) for six weeks 
Return rates 100% return rate in all subjects completing 
analysis (81/94) Failure to enter daily data for 
>10 days was considered non-compliant and 
resulted in exclusion. N=1 didn't comply, but 
unclear if this with question naire, diary, or low 
adherence. Subjects remunerated for completed 
log books 
- 
Roddey 
200229 
Acc G n=108, full-thickness rotator cuff tear 
patients undergoing arthroscopic 
repair, G1 n=54 58.7, (10.6), 35%f, G2 
n=54 57.2 (9.1), 39%f 
Home PT exercises, either 
through a videotape or 4 PT 
sessions for 6 mo  
  
Completion rates n=73/106 (68.9%) returned all four logs. 
Compliance criteria determined a priori: ‘‘fully 
compliant’’ = all 4 logs and 70% adherence, n=61; 
‘‘partially compliant’’ = 3-4 logs and 50-69% 
adherence, n=12; ‘‘noncompliant’’ = <3 logs or 
<50% adherence, n=33 (31.1%). 2 subjects lost to 
follow up. Telephone reminders used. Logs 
returned every 6 weeks with SAE 
- 
Sassi-
Dambron 
1994177 
Acc F, D n=57, symptomatic chronic obstructive 
pulmonary disease patients, n=42 
sample responding 61.4(7.6), 24%f 
Daily walks, initially 3 short 
walks increasing to one long 
walk of up to 30 mins  (also 
supervised exercise: treadmill 
and an upper-body ergometer, 
upper-body weight training 
Completion rates 42/57 had completed diaries "the others were 
either not collected or not completed" (numbers 
for each unclear) 
- 
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over 8 week block - not 
recorded in diary) 
Schachter 
200354 
Acc F, D n=143, sedentary women with 
fibromyalgia, groups (1) long bout 
exercise (LBE) (n=51) 41.3 (8.67) 
100%f; (2) short bouts exercise (SBE) 
(n=56) 41.9 (8.57), 100%f and (3) 
control (no exercise) (n=36)  42.5 
(6.69), 100%f 
16 week progressive low-
impact aerobics programme 
using a videotape, in long or 
short bouts   
Return rates 45/56 (80.4%) in short bout group, 42/51 
(82.4%) in long bout group completed the study 
and submitted logs (81.3% overall) (completion 
not defined).= 
- 
Shang 2009105 Acc F, D, 
I 
n=126, newly diagnosed cancer patients 
aged 21+ with no evidence of metastatic 
disease, scheduled to receive 
chemotherapy or radiotherapy, 60.2 
(10.6), 39%f 
Individualised home-based 
walking and muscle-
strengthening exercise program 
5 days per week, throughout 
cancer treatment (5-35 weeks). 
Control participants continued 
their usual physical activity." 
Completion rates 17 participants (13.49%, 4 (5.9%) in intervention, 
13 (22.4%) in control) had “significant” missing 
data for certain weeks. Missing data were imputed 
from telephone logs (correlated highly with 
exercise log on other weeks). Logs were mailed 
back at the end of each week. Research nurses 
would call if logs were not returned on time. 
- 
Webb-Peploe 
200032 
Acc F, D, 
I 
n=24, patients with ischaemic and 
idiopathic dilated cardiomyopathy, 53 
(SD NR), 4.2%f 
Progressive exercises and 
20min bicycle ergometry at 
least 5 days a week for 8 weeks  
Completion rates 18/24 (75%) completed diaries, 16/24 (66.7%) 
correctly filled out revolutions pedalled per day. 
Unclear if 18 participants completing diaries were 
same as included in final analysis 
- 
Williams Acc F, D, n=46, non-insulin dependent diabetes Usual exercise over 2 weeks Return rates Return rate = 100% (also fully completed, not - 
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1996114 I, O mellitus patients, 60.3 (SD NR), 45.7%f defined) 
Wilson 
2005110 
Acc F, D, 
I 
n=13, aged 18-65 who received blood 
stem cell or bone marrow transplant 
>6mo prior to participation and low 
leisure time physical activity, n=17 full 
sample, 48.9 (10.4), 64.7%f 
Exercise 3+ times/week for 
20mins continuously in their 
HR training zone for 12 weeks 
 
Return rates 9/13 (69.2%) returned completed exercise 
diaries. High number of withdrawals and refusals 
(76% intervention acceptability) 
- 
Yuen 201233 Acc F n=26 (intervention group), adults with 
systemic sclerosis, 51.9 (14.3), 80.8%f 
Daily orofacial exercises, teeth 
brushing and flossing for 6 mo   
Return rates Return rate = 11/13 (84.6%) 2 did not return 
monthly charts; unclear if all charts were returned 
for others. Diaries were posted (SAE provided) 
with telephone reminders 
- 
Bassett & Prapavessis’ scale high quality studies (n=3) 
Bassett 20112 
  
Int cons Gen n=70, patients with an ankle sprain 
undergoing PT, G1 35.9yrs (13.4), G2 
34.9yrs (12.2), G3 34.9yrs (13.1), 57%f 
Home; PT program with PMT, 
attention control or no 
information 
Cronbach’s alpha was 
calculated from the means of 
participants’ mean scores for 
each subscale  
α=0.63 G 
 Cons val Gen n=69, patients with an ankle sprain 
undergoing PT, (full sample n=70) G1 
35.9yrs (13.4), G2 34.9yrs (12.2), G3 
34.9yrs (13.1), 57%f 
Home; PT program with PMT, 
attention control or no 
information 
Intentions to attend clinic 
appointments and to adhere to 
home-based therapy (2 items 
based on Theory of Planned 
Behaviour, 7 point Likert scale)  
Home exercise subscale & intentions to attend 
clinic appointments r=0.24 (p=0.05)  
Home exercise subscale & intentions to adhere to 
home therapy r=0.25 (p=0.05)  
Ankle elevation adherence and intentions to 
adhere to home therapy r=0.38 (p=0.01) 
G 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
Other variables not correlated 
 Crit val Gen n=69, patients with an ankle sprain 
undergoing PT, (full sample n=70) G1 
35.9yrs (13.4), G2 34.9yrs (12.2), G3 
34.9yrs (13.1), 57%f 
Home; PT program with PMT, 
attention control or no 
information 
Ankle function (Lower Limb 
Task Questionnaire and Motor 
Activity Scale) at the end of the 
PT programme. 
No significant correlations G 
Bassett & Prapavessis’ scale low quality studies (n=1) 
Bassett 20073 Int cons Gen N=47, diagnosis of acute ankle sprain, 
30 (12.4), 40%f  
 
Clinic; participants randomised 
to home-based or clinic-based 
three-phase physical therapy 
programme 
Patients rated their adherence 
at the beginning of each clinic 
appointment. Means were 
calculated for each participant 
and subscale  
Cronbach’s α=0.78 F 
Borg 6-20 Rating of Perceived Exertion scale high quality studies (n=3) 
Miller 1985132 Crit val I n=113, healthy adults, f=64.8yrs (SD 
NR) m=64.3yrs (SD NR), 52%f  
Lab; walking on the spot for 
2min at brisk, comfortable pace 
Heart rate (Exersentry heart 
rate monitor)  
r=0.34 p=0.0002 E 
Crit val I n=89, healthy adults, f=64.8yrs (SD NR) 
m=64.3yrs (SD NR), 52%f 
Lab; 600m walk at brisk, 
comfortable pace 
Heart rate (Exersentry heart 
rate monitor). 
R=0.33 p=0.002  G 
Julius 2012133 Cons val I n=50,  65+ adults with mobility 
limitations, 76.8yrs (5.5), 66%f 
Lab; ~15m walk at self-
selected, comfortable pace 
Gait speed (GaitMatII) ρ=-0.16 (p=0.27) G 
Modified Gait Abnormality 
Rating Scale 
ρ=0.21 (p=0.15) G 
Energy cost of 3min treadmill 
walk at self-selected pace 
ρ=0.01 (p=0.95) G 
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(oxygen consumption by open-
circuit spirometry)  
Late Life Function and 
Disability Questionnaire 
Function subscale ρ=-0.17 (p=0.24) 
basic lower extremity subscale ρ=-0.20 (p=0.17), 
advanced lower extremity subscale ρ=-0.11 
(p=0.47), disability subscale ρ=-0.07 (p=0.61) 
G 
Survey of Activities and Fear of 
Falling in the Elderly 
Fear subscale ρ=0.26 (p=0.07), activity subscale 
ρ=0.13 (p=0.35), restriction subscale ρ=0.02 
(p=0.88) 
G 
Physical activity during daily 
activities (Actigraph 
accelerometer) 
ρ=0.30 (p=0.04) G 
Gait Efficacy Scale ρ=-0.33 (p=0.02) G 
Borg 6-20 scale low quality studies (n=57) 
Gamberale 
1972138 
Crit val I 
 
N=12, adult healthy men, 26.5 (SD NR, 
range 20-35), 0%f 
Lab; randomly assigned 6min 
exercise tasks including lifting 
weights, pushing a 
wheelbarrow and cycling  
Heart rate (telemetry, Medenik, 
Honeywell) at randomly chosen 
values for each workload 
Pearson’s: Wheelbarrow activity r=0.42, lifting 
weights r=0.64, cycle ergometer r=0.94 
P 
Goslin 1986139 Crit val 
 
I 
 
N=10, healthy Caucasian males, 24.3 
(2.8), 0%f 
 
Lab; treadmill tests with 
varying backpack loads and 
speeds  
Heart rate (Hewlett-Packard 
telemetry) 
Correlations: r=0.47  P 
Oxygen uptake (VO2), r=0.75 P 
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Ventilation index (VI) (open 
circuit chamber with Beckman 
OM-14 and LB-2 oxygen and 
carbon dioxide analysers). 
r=0.58 P 
Goss 2003184 Crit val I n=24, healthy adults, F=22.9 (5.1), 
M=22.4 (1.6), 50%f 
Lab; 12 6min exercise trials on 
a Nordic Track Total Body 
System, with different 
combinations of arm and leg 
exercises. Three six min 
exercise trials were completed 
per session, separate by >24hr. 
Oxygen consumption 
(ml/kg/min) - open circuit 
spirometry 
Pearson's r=0.52 P 
Oxygen consumption (%VO2 
peak) - open circuit spirometry 
r=0.54 P 
Respiratory exchange ratio - 
open circuit spirometry 
r=0.52 P 
Heart rate - Eaton Care 
Telemetry 
r=0.42 P 
Lagally 
2004185 
Crit val I n=20, 10 novice and 10 recreationally 
trained women,  full sample (n=28) 
novice 21.6 (1.5) 100%f, recreational 
21.9 (2.2) 100%f 
Lab; 8 repetitions at 60% 1RM, 
6 repetitions at 80% 1RM of a 
bench press exercise 
Muscle activity using 
electromyography (MP100 
EMG system) 
No significant correlations (statistics NR) between 
RPE and EMG 
P 
O’Neill 
1992134 
Crit val 
 
I 
 
N=48, healthy women with 
uncomplicated singleton pregnancies, 
30(5), 100%f 
Location NR; aerobics class at 
13-28 weeks gestation, RPE 
estimated at the end of each 
exercise track  
Heart rate (Polar Sports Tester 
PE3000) 
Pearson’s r=0.27 (p>0.05) 
 
F 
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O’Neill 
1992134 
Crit val 
 
I 
 
N=11, healthy women with 
uncomplicated singleton pregnancies, 
30(3), 100%f 
Location NR; 26min treadmill 
exercise at 23-28 and 34-37 
weeks gestation and again at 8+ 
weeks after delivery.  
ECG (Hewlett Packard 1405A) Pearson’s: r=0.83 p<0.01  P 
O’Neill 
1992134 
Crit val 
 
I 
 
N=12, healthy women with 
uncomplicated singleton pregnancies, 
32(4), 100%f 
Location NR; 12min exercise on 
a bicycle ergometer at 34-38 
weeks gestation and at 8+ 
weeks postpartum 
ECG (Hewlett Packard 1405A) Pearson’s: r=0.74, p<0.015 P 
O’Neill 
1992134 
Crit val 
 
I 
 
N=24, healthy women with 
uncomplicated singleton pregnancies, 
30(3), 100%f 
Location NR; 30min circuit 
training between 20-28 weeks 
gestation 
Heart rate (Polar Sports Tester 
PE3000) 
Pearson’s r=0.39 p>0.05 P 
O’Neill 
1992134 
Crit val I 
 
N=29, healthy women with 
uncomplicated singleton pregnancies, 
31(4), 100%f 
Location NR; aerobics class at 
29-39 weeks gestation 
Heart rate (Polar Sports Tester 
PE3000) 
Pearson’s r=0.35 p>0.05 P 
Pandolf 
1978186 
Crit val I n=15, highly fit males, 20.2 (SD NR, 
range 18-22), 0%f 
Lab; climbing and descending a 
laddermill and stool stepping at 
three different rates, using foot 
over foot climbing and both feet 
to same rung climbing, for five 
mins each 
Heart rate (Sanborn model 100 
Viso Recorder) 
Regression: foot over foot climb descent r=0.56, 
ascent r=0.74, both feet to same rung descent 
r=0.23, ascent r=0.53, stool stepping r=0.74 
P 
Oxygen consumption (expired 
air and spirometer) 
Foot over foot climb descent r=0.60, ascent r=0.72, 
both feet to same rung descent r=0.45, ascent 
r=0.63, stool stepping r=0.82. 
P 
Pollock Crit val I n=13 healthy adults, 53.5 (5.4), 85%f Lab; WiiFit session, including Heart rate (30s left radial pulse Pearson's r=0.32 (p value not calculated due to P 
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2013135 5min warm up, exercise from 
two WiiFit categories for 15min 
each, 5min cool down, 
performed on two days with 
different exercises. RPE 
assessed during final 30s of 
each exercise category.  
palpation by experienced study 
coordinators) 
repeated measures, mixed effects model analysis 
found significant association p<0.001) 
Row 2012187 Crit val I n=21, healthy older adults, 76.6 (5.5), 
43%f 
Fitness centre; concentric and 
eccentric resistance training 
using a seated leg press with 
50% to 150% body weight 
loads (4-5 reps), administered 
in a random order 
%1RM lifted in a second 
session that equated to the 
loads lifted in the first session. 
Lowest load in each 10% range 
and corresponding RPE were 
used.  
Regression: average RPE for each load strongly 
predicted average %1RM for each load (R2 = 
99.5%, p<0.001) 
P 
Schaeffer 
1995136 
Crit val I N=16, healthy women with previous 
instructional experience in aerobic 
dance, 23.0 (3.7), 100%f 
Lab; 8 trials - 1min each for 8 
minutes x 3 (T1, T2, T3) 
including 4 steps (jumping jack, 
power jack, jog and march) at 2 
cadences (124 or 138 bpm) 
along with a leader 
Heart rate (CIC Polar heart 
monitor) 
T1: r=-0.18, T2 r=0.01, T3 r=0.26. Partial 
correlations controlling for absolute oxygen 
consumption: T1: r=-0.16, T2 r=0.02, T3 r=0.25 
P 
Absolute VO2 consumption  
(Sensormedics, 2900 
measurement cart) 
T1: r= -0.13, T2 r= -0.01, T3 r=0.14 P 
Relative VO2 consumption 
(Sensormedics, 2900 
T1: r=0.25, T2 r=0.20, T3 r= -0.02 P 
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measurement cart) 
%VO2 max(Sensormedics, 
2900 measurement cart) 
T1: r=0.30, T2 r=0.08, T3 r=0.01 P 
%max HR (CIC Polar monitor) T1: r=-0.02, T2 r=-0.02, T3 r=0.33. Partial 
correlations controlling for absolute oxygen 
consumption T1 r= -0.03, T2 r= -0.02, T3 r=0.34 
P 
Volume of carbon dioxide 
expired 
 
T1: r=-0.02, T2 r=0.04, T3 r=0.21. Partial 
correlational analyses controlling for absolute 
oxygen consumption T1 r=0.33, T2 r=0.25, T3 
r=0.35 
P 
Ventilation rate (Sensormedics, 
2900 measurement cart) 
T1: r=0.23, T2 r=0.20, T3 r=0.32. Partial 
correlational analyses controlling for absolute 
oxygen consumption T1 r=0.51, (P<0.05) T2 
r=0.48, T3 r=0.33 
P 
O2 pulse T1: r=-0.01, T2 r= -0.05, T3 r=0.01 P 
Gross energy cost (kcal/min) T1: r= -0.11, T2 r=0.00, T3 r=0.22. Partial 
correlational analyses controlling for absolute 
oxygen consumption T1 r=0.35, T2 r=0.27, T3 
r=0.20 
P 
Net energy cost (kcal/min) T1: r= 0.15, T2 r= -0.13, T3 r=0.02. Partial 
correlational analyses controlling for absolute 
P 
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oxygen consumption T1 r=0.08, T2 r= -0.39, T3 r= 
-0.39 
Respiratory exchange ratio 
(Sensormedics, 2900 
measurement cart) 
T1: r=0.37, T2 r=0.34, T3 r=0.43. Partial 
correlational analyses controlling for absolute 
oxygen consumption T1 r=0.40, T2 r=0.34, T3 
r=0.47 
P 
Schaeffer-
Gerschutz 
2000137 
Crit val I N=25, aerobically trained women, 21.0 
(1.0), 100%f 
Lab; 4 combinations of 3min 
aerobic steps include dynamic 
(D) and static (S) high and low 
impact arm exercises in a 
random order, following 
videotaped directions and with 
a 3min break in between 
Heart rate (Quinton 4000 ECG) Pearson’s correlations High impact: D r=0.23, S 
r=0.34, Low impact D r=0.20, S r= -0.14  
P 
Percentage maximum heart 
rate (Quinton 4000 ECG) 
High impact: D r=0.27, S r=0.43 (sig p<0.03), Low 
impact D r=0.19, S r= -0.18 
P 
Relative oxygen consumption 
(Sensormedics, 2900 
measurement cart) 
High impact: D r= -0.07, S r=0.00, Low impact D 
r=0.06, S r= 0.15 
P 
Percentage of maximum oxygen 
consumption (Sensormedics, 
2900 measurement cart) 
High impact: D r=0.12, S r=0.16, Low impact D 
r=0.14, S r= 0.15 
P 
Absolute oxygen consumption  
(Sensormedics, 2900 
measurement cart) 
High impact: D r= -0.12, S r= -0.20, Low impact D 
r= -0.05, S r= 0.13 
P 
Ventilation (Sensormedics, 
2900 measurement cart) 
High impact: D r=0.36 S r=0.09, Low impact D 
r=0.25, S r= 0.42 (sig p<0.03) 
P 
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age, %female) 
Activity Comparator Statistic and outcome Qual 
Ventilatory equivalent per 
oxygen consumption 
(Sensormedics, 2900 
measurement cart) 
High impact: D r=0.62, S r=0.40, Low impact D 
r=0.39, S r= 0.45 (all p<0.03) 
P 
Stamford 
1976142 
Crit val I n=14, female undergraduate students, 
18.7 (SD NR), 100%f 
Lab; 6 cycling, treadmill 
walking, treadmill jogging and 
stool stepping tasks performed 
at a variety of intensities and 
for differing lengths of time in a 
randomised order (including 
interval tasks).  
Identical tasks were performed 
with interval RPE rated every 
minute of exercise 
Pearson's correlations ranged between 0.71 to 
0.90 for all activities (p<0.01) 
P 
Eng 2002188 Cons val I n=25, individuals >1 year post-stroke, 
62.6 (8.5), 32%f 
Lab; 6 minute walk test and 12 
minute walk test, estimation of 
exertion at end of each test 
Distance walked (m), measured 
by amount undertaken on 42m 
path 
Pearson's 6MWT r= -0.10, 12MWT r= -0.06 P 
Fry 200518 Cons val I n=12, adults with MS able to ambulate 
for >6min, 47.3 (10.6), 75%f 
Lab; static standing balance test  Test scores (best out of 3) Spearman's ρ= -0.72 (p=0.01) P 
Lab; functional stair test  Test scores (best out of 3) ρ=0.70 (p=0.01) P 
Lab; sit-to-stand test  Test scores (best out of 3) ρ=0.51 (p=0.09) P 
Lab; 6-minute walk test 
(metres) 
Test score ρ= -0.31 (p=0.33) P 
Okhovatian 
1997145 
Cons val I n=10, able-bodied subjects wearing a 
knee-ankle-foot orthosis and using 
Location unclear; 5 min of 
walking around looped track at 
Speed (calculated by 
simultaneously recording time 
Correlations r=0.733 (p<0.01) P 
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age, %female) 
Activity Comparator Statistic and outcome Qual 
crutches, 26.7 (SE 1.3), gender NR preferred speed, slow speed 
and fast speed 
and distance) 
Hills 2006146 Resp to 
change 
I n=50, obese (n=30, age=47.8 (10.8), 
gender NR) or non-obese (n=20, 36.9 
(12.4), gender NR) sedentary non-
smokers 
Grass track; walking on a level 
2km once each day for three 
days, at "walking for pleasure" 
speed for first two days and 
maximum pace manageable on 
last day 
Walking for pleasure speed vs 
maximum pace  
Mean RPE values significantly higher for both 
groups (F=133,1, p<0.01) 
P 
Kravitz 
2003147 
Resp to 
change 
I n=18, men and women aged 20-32 from 
boxing exercise classes, 22.0 (2.8), 33%f 
Lab; 2min boxing bouts at 
varying tempos 
60, 72, 84, 96, 108 and 120 
punches per min tempos, 
established by a metronome 
Friedman non-parametric ANOVA. Significant 
differences (p<0.05) between RPE ranks (2.3, 2.4, 
2.9, 3.2, 4.2 for each respective tempo) 
P 
Lagally 
2002148 
Resp to 
change 
I n=19, healthy adults, F=21.8 (2.7), 
M=23.2 (3.6), 47%f 
Lab; 7 resistance exercises  15 repetitions of 30%1RM, 5 
repetitions of 90%1RM 
ANOVA: All seven exercises showed significantly 
higher RPE at higher intensity (p<0.01) 
P 
Lagally 
2004185 
Resp to 
change 
I n=28, 14 novice and 14 recreationally 
trained women,  novice 21.6 (1.5) 
100%f, recreational 21.9 (2.2) 100%f 
Lab; 8 repetitions at 60% 1RM, 
6 repetitions at 80% 1RM of a 
bench press exercise 
Increase from 60% 1Rm to 
80%1RM 
ANOVA - RPE significantly higher (11.29 vs 13.39, 
p<0.01) at 80% 1RM  
P 
Leidy 1997149 Resp to 
change 
I n=20, healthy adults, 35.8 (12.4), 80%f Lab; 2mins of: Light activities: 
conversing, writing, reading, 
playing cards, standing and 
waiting; moderate: polishing, 
sweeping, dressing, folding 
Light, moderate and heavy 
activities 
Friedman non-parametric ANOVA: RPE varied by 
activity intensity in the order hypothesised 
(p<0.001). Post-hoc tests found significant 
differences between light and heavy and heavy 
and moderate activity.  
P 
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age, %female) 
Activity Comparator Statistic and outcome Qual 
clothes, level walking; heavy: 
stair climbing, hustle walking, 
pushing and pulling a vacuum, 
carrying groceries, lifting and 
moving objects 
Schaeffer-
Gerschutz 
2000137 
Resp to 
change 
I N=25, aerobically trained women, 21.0 
(1.0), 100%f 
Lab; 4 combinations of 3min 
aerobic steps include dynamic 
and static high and low impact 
arm exercises in a random 
order, following videotaped 
directions and with a 3min 
break in between 
High vs low impact exercises ANOVA: 10.92 and 12.16 (high impact) vs 9.00 and 
9.36 (low impact). F=34.72 (p<0.03) 
P 
Vasquez 
2013150 
Resp to 
change 
I n=12, healthy males with >2yrs 
experience of back squats, 21.9 (1.3), 
0%f 
Lab; back squats: 3 repetitions 
of 50%1RM and to volitional 
failure, repeated with 70%1RM 
and 90%1RM in a randomised 
order with 10min rest in 
between 
Hypothesised differences 
between 3 repetitions at each 
intensity but not reps to 
volitional failure 
ANOVA and one within-subjects factor - significant 
main effect for condition (F=42.8, p<0.001) and 
significant differences between 3 repetition 
intensities (50=9.5, 70=11.7, 90=15.3, p<0.001). 
No sig differences between those to volitional 
failure (50=16.7, 50=16.5, 90=17.4). 
P 
Dawes 
2005189 
FCV I n=19, individuals with acquired brain 
injury (age range 30-60, 37%f), n=16, 
individuals with chronic low back pain 
Lab; participants asked to 
imagine they are cycling up a 
progressively steeper hill to a 
VAS and percentage ratings All groups followed an S-shaped curve increase 
from nothing to maximum compared to the mean 
VAS. Confidence intervals were larger in the centre 
P 
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age, %female) 
Activity Comparator Statistic and outcome Qual 
(age range 23-55, 50%f), n=20 healthy 
students (age range 19-25, 50%f)  
point where they are unable to 
continue. Each verbal anchor, 
administered in a random 
order, from the 6-20 was rated 
on a 20-cm VAS (limits nothing 
at all and maximum) and given 
a percentage rating. New VAS 
and blank cards were given for 
each anchor and the previous 
one hidden. Participants rated 
both breathlessness and leg 
fatigue, though as there were no 
significant differences only 
breathlessness and the VAS 
were used in the comparison.  
of the scale and significant differences were found 
between some anchors but not others, though this 
varied between groups.  
Fry 200518 TRR I n=12, adults with MS able to ambulate 
for >6min, 47.3 (10.6), 75%f 
Lab; Static standing balance test 
(best trial out of 3) 
1 week Spearman's: ρ=0.77 (p=0.00) P 
Lab; functional stair test (best 
trial out of 3) 
1 week ρ=0.86 (p=0.00) P 
Lab; sit-to-stand test (best trial 
out of 3) 
1 week ρ=0.70 (p=0.01) 
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Activity Comparator Statistic and outcome Qual 
6-minute walk test (rated at 
end of each individual test) 
1 week ρ=0.96 (p=0.00) P 
Leidy 1997149 TRR I n=18, healthy adults, full sample 
(n=20): 35.80 (12.37), 80%f 
Lab; 2 mins of each activity. 
Light activities: conversing, 
writing, reading, playing cards, 
standing and waiting; 
moderate: polishing, sweeping, 
dressing, folding clothes, level 
walking; heavy: stair climbing, 
hustle walking, pushing and 
pulling a vacuum, carrying 
groceries, lifting and moving 
objects 
Within 1 week (mean = 2.8 
(1.7)) 
Unclear; no significant differences in RPE (data 
NR) 
P 
Row 2012187 TRR I n=21, healthy older adults, 76.6 (5.5), 
43%f 
Fitness centre; concentric and 
eccentric resistance training 
using a seated leg press with 
50% to 150% body weight 
loads (4-5 repetitions), 
administered in a random order 
Second presentation of the 
same five loads at the end of the 
session 
ICC=0.729 P 
Skatrud-
Mickelson 
TRR I n=21, healthy adults aged 18-74 of all 
BMI classes, full sample n=117 (61.2% 
Lab; 0.29 mile indoor lap 1) 
very slow walk, 2) normal 
Mail survey 6-8 weeks later 
asking participants to recall the 
Wilcoxon signed ranks test: significant difference 
between median ranks (p=0.02) between times 
P 
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Activity Comparator Statistic and outcome Qual 
2011152 aged 18-49, 38.8% aged 50-74) 57%f  paced walk, 3) brisk walk or jog RPE for the three laps 
Stamford 
1976142 
TRR I n=14, female undergraduate students, 
18.7 (SD NR), 100%f 
Lab; 2 x one set of cycle 
ergometer tasks including a 
range of intensities  
Part of 12 work tasks in a 
randomised order over 4 
sessions - could be in the same 
session or 2-8 days later 
Pearson's r=0.90 P 
Hills 2006146 ME I n=50, obese (n=30, age=47.8 (10.8), 
gender NR) or non-obese (n=20, 36.9 
(12.4), gender NR) sedentary non-
smokers 
Grass track; walking on a level 
2km track once each day for 
two days, at "walking for 
pleasure" speed  
 
1 day Mean bias = -0.1, LOA = 2.1 F 
Yamax Digiwalker CW series high quality studies (n=1) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
Kinunnen 
2011154 
Crit val F, O n=58, overweight and obese 
pregnant women (BMI>25), median 
age 32 yrs (IQR 27-36), 100%f 
Home/community; everyday 
activity for 4 days  
GT1M Actigraph (time in 
sedentary, light, moderate 
and vigorous activity and step 
count) 
LOA for mean value (6026 steps) =  
-2690 to 2656 steps/day.  
Lowest step count 906 steps (LOA -297 to 4897) 
Highest 12018 steps (LOA -4753 to 33)  
No effect of BMI and gestational age.  
Steps/day Spearman’s ρ=0.78 (0.59-0.90) p<0.001 
>=8000 steps/day (CW) and >=30min moderate-
vigorous physical activity per day (GT1M) k=0.45 
(0.24-0.67), >8000 or <8000 steps/day (CW & 
GT1M) k=0.63 (0.43 to 0.83)  
Wilcoxon signed-rank test for absolute step count 
between devices = medians 5961 vs 5687 (p=0.37) 
G 
Yamax Digiwalker CW series low quality studies (n=2) 
Martin 
2012155 
Crit val F  n=18, community dwelling older adults, 
BMI<30, able to ambulate without 
assistance for >100m, 63.6 (SD NR), 
67%f 
Lab; walks at 50, 66 and 80 
steps/min (in time with 
metronome) and self-selected 
speed on a 40m indoor track (8 
total walks) 
Average of 2 observers with 
handheld counters (if within 
5% steps). 100% agreement for 
88% trials, no discrepancies 
>5%.  
Percentage error 
50 steps/min = 66.8%, 66= 40.8%, 80=22.7% and 
SS= 4.8%  
P 
Martin 
2012155 
Inter-
rater rel 
F  n=18, community dwelling older adults, 
BMI<30, able to ambulate without 
assistance for >100m, 63.6 (SD NR), 
Lab; walks at self-selected 
speed on a 40m indoor track  
Three pedometers of the same 
brand randomly assigned to a 
participant and compared  
ICC=0.70 (0.20-0.89) P 
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Activity Comparator Statistic and outcome Qual 
67%f 
Yamax Digiwalker CW series acceptability studies (n=1) 
Kinunnen 
2011154 
Acc F, O n=93, overweight and obese pregnant 
women, median 13 weeks' gestation, 
median age 32 (IQR 27-36), 100% f 
Steps per day averaged over 4 
days 
Missing data n=3 women did not have pedometer data (unclear 
if out of 61 with complete accelerometer data 
(worn simultaneously) or out of 93 original 
sample). Accelerometer had much higher missing 
data. Authors discuss that in some cases step 
counts were much lower on pedometer than 
accelerometer, suggesting non-wear or a tilt angle 
that did not properly detect steps 
- 
Joint Protection Behaviour Assessment low quality studies (N=22) 
Hammond 
1999b157 
Cons val A 
 
 
n=35, RA patients with wrist or 
metacarophalangeal involvement and 
some restriction in ability to perform 
ADLs; 55.17 (9.39), 83%f 
 
Home; use of joint protection in 
ADLs after a  group education 
programme 
 
Grip strength (digital 
dynamometer) 
Spearman’s ρ=-0.11 (NS) F 
Hand Joint Alignment and 
Motion Sale (ROM and 
deformity) 
ρ=0.06 (NS) F 
Frequency of joint protection 
practice (7pt scale 1=once a 
week, 7=daily) 
ρ=0.47 (significant). Also predicted in regression 
model (β=5.35, p=0.02) 
P 
Hand pain (VAS) ρ=-0.02 F 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Reference MPA Para Population (n, descriptor, mean (SD) 
age, %female) 
Activity Comparator Statistic and outcome Qual 
Hammond 
2002190 
Cons val 
 
A 
 
n=30; RA diagnosis with wrist or hand 
involvement, >18, able to perform 
household tasks but hand pain on 
activity; 52.3 (12.08), 90%f 
 
Home; use of joint protection in 
ADLs after an education 
programme run by OTs 
 
Perceived helplessness 
(Rheumatology Attitudes Index 
Part 1) 
ρ= -0.43 (p=0.03) F 
Perceived control of arthritis 
(Rheumatology Attitudes Index 
Part 2) 
ρ= -0.38 (p=0.05) F 
Attending more sessions ρ=0.39 (p=0.04) F 
Change in overall pain (VAS) ρ= -0.36 (p=0.07) P 
Change in hand pain (VAS) ρ= -0.35 (p=0.08) P 
Hammond 
1999a156 
Cons val A N=24, Group A: "Normal" - no RA or 
history of hand dysfunction, 40.5 (7.9), 
83%f 
Use of joint protection in ADLs Extreme groups; Group A and B 
JPBA scores compared  
Mann-Whitney U:  
Group A median = 0%, IQR = 0%.  
Group B median = 23.01%, IQR 6.48-31.88%  
U=175, p<0.0001 
 
F 
A N=20, Group B: RA diagnosis by 
consultant rheumatologist, history of 
hand dysfunction, difficulty with kitchen 
activities, 57.2 (9.9), 65%f 
Use of joint protection in ADLs 
Hammond 
1999a156 
Cons val A N=35, rheumatoid arthritis patients, 
55.2 (9.4), 83%f 
Use of joint protection in ADLs Hand pain (VAS, HAQ pain 
scale) 
Spearman’s VAS ρ=0.51 (p<0.001), functional pain 
score ρ=0.38 (p<0.05) 
F 
Hand impairment (Joint 
Alignment and Motion Scale) 
ρ=0.22 (NS) F 
Grip strength (Digital ρ=-0.54 (p<0.001) F 
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Activity Comparator Statistic and outcome Qual 
Dynamometer) 
Number of painful joints (ACR 
criteria) 
ρ=0.41 (p<0.01) F 
Functional disability (HAQ)  ρ=0.33 (p<0.05) F 
Hammond 
1999a156 
FCV A Face validity: NR 
Content validity: n=7 experienced 
rheumatology OTs 
Use of joint protection in ADLs  Face validity: 20 JPBA tasks 
rated according to whether 
they involved the 5 joint 
principles. 
 
Content validity: 124 codes of 
behaviour definitions (normal, 
joint protection and functional 
adaptations) were developed 
from literature and video 
observations of RA. Seven 
rheumatology OTs reviewed 
each behaviour code and scored 
it as correct, partially correct or 
incorrect. 
Each task was rated as being appropriate for 
assessing 2-5 joint protection principles 
 
Kappa: κ=0.6 overall (range for individual tasks 
0.46-1.00 (all p<0.01)). 41.13% (51/124) codes 
had total agreement. 
F 
Klompenhou
wer 2000159 
Resp to 
change 
A N = 6 participants: healthy adults 
(junior OT students), age NR, gender NR 
Lab; 3x3 groups of observers 
each rated a videotape of 6 
JPBA tasks performed with 1) 
no joint protection knowledge, 
Mean scores  
1) 0.06 
P 
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Activity Comparator Statistic and outcome Qual 
N=9 observers (different junior OT 
students), age NR, gender NR 
 
unique performances and 2 
duplicates of JPBA 
performances 
2) after 1 hr joint protection 
instructions and 3) with verbal 
guidance. Unique rating scores 
compared at each manipulated 
level. >0.20 considered 
clinically significant difference.  
2) 0.38 
3) 0.82 
All >0.20 difference 
Hammond 
1999a156 
TRR A N=20, Rheumatoid arthritis diagnosis, 
history of hand dysfunction, difficulty 
with kitchen activities, 57.2 (9.9), 65%f 
Use of joint protection in ADLs Time interval: approx. 8 weeks  Spearman’s ρ=0.91 p<0.0001 P 
Hammond 
1999a156 
Inter-
rater rel 
A 
 
4 OTs with no recent rheumatology 
experience, 1 researcher, age and 
gender of OTs and sample NR 
Use of joint protection in ADLs 10 videotaped JPBAs of people 
with RA were scored by each 
OT with regular consultation of 
the manual 
Kappa:  OT 1 κ=0.88, 94.1%; OT 2 κ=0.80, 92.1%; 
OT 3 κ=0.71, 87.5%; OT 4 κ=0.68, 81.6% 
P 
Klompenhou
wer 2000159 
Intra-
rater rel 
A N = 6 participants: healthy adults 
(junior OT students), age NR, gender NR 
N=9 observers (different junior OT 
students), age NR, gender NR 
Lab; JPBA tasks performed with 
1) no joint protection 
knowledge, 2) after 1 hr joint 
protection instructions and 3) 
with verbal guidance 
3x3 groups of observers each 
rated a videotape of 6 unique 
performances and 2 duplicates; 
duplicates assessed  
ICC = 0.97 (0.92-0.99) P 
Klompenhou
wer 2000159 
Inter-
rater rel 
A N = 6 participants: healthy adults 
(junior OT students), age NR, gender NR 
N=9 observers (different junior OT 
Lab; JPBA tasks performed with 
1) no joint protection 
knowledge, 2) after 1 hr joint 
3x3 groups of observers each 
rated a videotape of 6 unique 
performances and 2 duplicates; 
ICC = 0.93 (0.83-0.97) P 
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Activity Comparator Statistic and outcome Qual 
students), age NR, gender NR protection instructions and 3) 
with verbal guidance 
unique performances assessed 
Klompenhou
wer 2000159 
Int cons A N = 6 participants: healthy adults 
(junior OT students), age NR, gender NR 
N=9 observers (different junior OT 
students), age NR, gender NR 
 
Lab; JPBA tasks performed with 
1) no joint protection 
knowledge, 2) after 1 hr joint 
protection instructions and 3) 
with verbal guidance 
3x3 groups of observers each 
rated a videotape of 6 unique 
performances and 2 duplicates; 
unique rating scores divided 
into S-JPBA and A-JPBA 
Cronbach’s alpha = 0.95 P 
Joint Protection Behaviour Assessment acceptability studies (N=1) 
Hammond 
200412 
Acc A n=127, rheumatoid arthritis patients 
experiencing hand pain on activity; 
mean age for control group: 51 years  
range: (45-59.25); mean age for joint 
protection programme: 52 years range: 
(44-59), 76%f 
Using joint protection strategies 
in ADLs for 48mo after a 
standard arthritis education 
programme, including 2.5hrs of 
joint protection  
Performance rates 83/127 agreed to be recorded performing JPBA   
(44/49 at 48mo in intervention, 39/58 in control) 
Unclear if others were assessed but not videoed. 
High refusal in standard group may relate to non-
intervention 
- 
Polar A1 series HRMs acceptability studies (n=1) 
Segerstahl 
2011161 
Acc F, D, 
I 
n=30, healthy  adults sampled on 
exercise background and motivation, 
30.0 (6.3), 50%f 
Structured and non-structured 
exercise, including swimming, 
running, cycling, strength 
training, climbing, horseback 
riding, walking, soccer, 
Wear rates, experiences of 
using the HRM 
HRM used in 291/383 (76.0%) of sessions 
reported in a diary. 28/30 (93.0%) chose to use it 
regularly. 92 (24.0%) reported sessions were 
carried out without the HRM 
 
- 
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basketball and gardening, over 
3 weeks 
Semi-structured interviews and diaries: 
 
Common reasons for non-use were: 
inconvenience/awkwardness associated with the 
chest strap, perceived unsuitability of heart rate 
monitoring for specific sports such as rock 
climbing or windsurfing, lack of time or forgetting 
to bring it along when exercising 
 
Benefits to HRM: monitors helped understand 
cause and effect in exercise behaviour, challenge 
or validate subjective feelings, optimise 
performance, highlight training patterns, was 
motivational and fun and offered a sense of 
accomplishment.  
 
Limitations: lack of surety about the 
appropriateness of the monitor's guidance and 
whether it was specific enough, further detail 
needed in manuals about target behaviours, 
unsuitability for certain situations, data 
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incompleteness and privacy concerns. 
 
Participants were highly motivated, young, fit, 
healthy and computer literate. 66.7% had prior 
experience of using a HRM. 
 
Abbreviations: MPA=measurement property assessment, Crit val=criterion validity, Cons val=construct validity, FCV=face and content validity, Resp to change=responsiveness to change, TRR=test-
retest reliability; rel=reliability; Int cons=internal consistency, ME=measurement error, NR=not reported, Para=parameter assessed, F=frequency, D=duration, I=intensity, A=accuracy, Gen=general 
adherence, O=other, n=number of participants, SD=standard deviation,G1=group 1, %f=percentage female, Qual=COSMIN quality rating (F=Fair, P=Poor), ICC=intra-class correlation coefficient, 
LOA=limits of agreement, SAM=StepWatch Activity Monitor, PETS=Problematic Experiences of Therapy Scale, JPBA=Joint Protection Behaviour Assessment, RPE=rating of perceived exertion, 
ADL=activities of daily living, HAQ=health assessment questionnaire, VAS=visual analogue scale, NS=non-significant, m=metre, s=seconds, min=minutes, hrs=hours, mo=months, 
mph=miles per hour, RCT=randomised controlled trial, 1RM=1 repetition maximum  
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Supplementary File 1: List of search terms  
Phase 1 Search 
CENTRAL, EED and HTA (2000-April 2013) 
(Title, abstract, keywords: “patient compliance” OR Title, abstract, keywords: compliance 
OR Title, abstract, keywords:  adherence) AND (All text: “rehabilitation” OR All text: 
rehabilitation) 
 
Phase 2 Searches (Medline example) 
Search strategies were adapted with headings relevant to each database.  
Publication type 
1. Validation studies 
 
MeSh 
1. Reproducibility of results 
2. Psychometrics 
3. Observer variation 
4. Discriminant analysis 
 
Ti+ab 
5. Reproducib* 
6. Psychometr* 
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7. Clinimetri* 
8. Clinometr* 
9. Observer variation 
10. Reliab* 
11. Valid* 
12. Coefficient 
13. “internal consistency” 
14. (Cronbach* AND (alpha OR alphas)) 
15. “item correlation” 
16. “item correlations” 
17. “item selection” 
18. “item selections” 
19. “item reduction” 
20. “item reductions” 
21. Test-retest 
22. (test AND retest) 
23. (reliab* AND (test OR retest)) 
24. Stability 
25. Interrater 
26. Inter-rater 
27. Intrarater 
28. Intra-rater 
29. Intertester 
30. Inter-tester 
31. Intratester 
32. Intra-tester 
33. Interobserver 
34. Inter-observer 
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35. Intraobserver 
36. Intra-observer 
37. Intertechnician 
38. Inter-technician 
39. Intratechnician 
40. Intra-technician 
41. Interexaminer 
42. Inter-examiner 
43. Intraexaminer 
44. Intra-examiner 
45. Interassay 
46. Inter-assay 
47. Intraassay 
48. Intra-assay 
49. Interindividual 
50. Inter-individual 
51. Intraindividual 
52. Intra-individual 
53. Interparticipant 
54. Inter-participant 
55. Intraparticipant 
56. Intra-participant 
57. Kappa 
58. Kappa’s 
59. Kappas 
60. “coefficient of variation” 
61. Generaliza* 
62. Generalisa* 
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63. Concordance 
64. (intraclass AND correlation*) 
65. Discriminative 
66. “known group” 
67. “Factor analysis” 
68. “Factor analyses” 
69. “factor structure” 
70. “factor structures” 
71. Dimensionality 
72. Subscale* 
73. “multitrait scaling analysis” 
74. “multitrait scaling analyses” 
75. “Item discriminant” 
76. “Interscale correlation” 
77. “Interscale correlations” 
78. ((Error OR errors) AND (measure* OR correlat* OR evaluat* OR accuracy* OR accurate OR 
precision OR mean)) 
79. “individual variability” 
80. “interval variability” 
81. “rate variability” 
82. “variability analysis” 
83. (uncertainty AND (measurement OR measuring)) 
84. “standard error of measurement” 
85. Sensitiv* 
86. Responsive* 
87. (limit AND detection) 
88. “minimum detectable concentration” 
89. Interpretab* 
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90. (small* AND (real OR detectable) AND (change OR difference)) 
91. “Meaningful change” 
92. “minimal important change” 
93. “minimal important difference” 
94. “minimally important change” 
95. “minimally important difference” 
96. “minimal detectable change” 
97. “minimal detectable difference” 
98. “minimally detectable change” 
99. “minimally detectable difference” 
100. “minimal real change” 
101. “minimal real difference” 
102. “minimally real change” 
103. “minimally real difference” 
104. “ceiling effect” 
105. “floor effect” 
106. “item response model” 
107. IRT 
108. Rasch 
109. “Differential item functioning” 
110. DIF 
111. “computer adaptive testing” 
112. “Item bank” 
113. “cross-cultural equivalence” 
114. qualitative 
115. interpret* 
116. rating* 
117. attach* 
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118. meaning* 
119. impact* 
120. burden 
121. feasib* 
122. “missing data” 
123. “missing values” 
124. “data loss” 
125. (response OR non-response OR nonresponse) 
126. “refusal rate” 
127. understand* 
128. completion 
129. comprehens* 
130. wear 
131. non-wear 
132. nonwear 
133. comfort* 
134. discomfort 
135. eas* 
136. appearance 
137. safe* 
138. (location OR placement) 
139. size 
140. conceal* 
141. usab* 
142. utility 
143. satisf* 
144. accepta* 
145. willing* 
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146. ability 
147. benefit 
148. performance 
149. obtrusive* 
150. pilot* 
151. workload 
 
Text word (TX) 
1. Agreement 
2. Precision 
3. Imprecision 
4. “precise values” 
5. Repeatab* 
6. ((replica*  OR repeated) AND (measure OR measures OR findings OR result OR results OR 
test OR tests)) 
All the above terms were searched using OR, and the exclusion filter was applied using NOT.  
Exclusion filter (All terms combined using OR) 
Publication type 
1. “addresses” 
2. “biography” 
3. “case reports” 
4. “comment” 
5. “directory” 
6. “editorial” 
7. “festschrift” 
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8. “interview” 
9. “lectures” 
10. “legal cases” 
11. “legislation” 
12. “letter” 
13. “news” 
14. “newspaper article” 
15. “patient education handout” 
16. “popular works” 
17. “congresses” 
18. “consensus development conference” 
19. “consensus development conference, nih” 
20. “practice guideline” 
 
MeSH 
21. NOT (“animals” NOT “humans”) 
 
Measure search terms 
 Problematic 
experiences of 
therapy scale 
TI, AB “problematic experiences  of therapy scale” 
StepWatch Activity 
Monitor  
 
TI, AB “step activity monitor” OR stepwatch OR (monitor AND orthocare) OR 
(monitor AND cyma) OR (monitor AND modus) OR (SAM AND monitor* AND 
step) 
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Adherence diary 
 
 
TI, AB “Exercise diary” OR “Exercise diaries” OR “Home diary”  OR “Home 
diaries” OR ((Logbook OR logbooks) AND (adherence OR compliance OR 
activity OR exercise)) OR “Activity diary” OR  “Activity diaries” OR “Activity 
log” OR “Activity logs” OR (“Treatment log” AND (home OR adherence OR 
exercise OR compliance)) OR (“Treatment logs” AND (home OR adherence OR 
exercise OR compliance)) OR (“Treatment diary” AND (home OR adherence OR 
exercise OR compliance)) OR (“Treatment diaries” AND (home OR adherence 
OR exercise OR compliance)) OR “Compliance diary” OR “Compliance diaries” 
OR “Adherence diary” OR “Adherence diaries” OR “Adherence log” OR 
“Adherence logs” OR “Compliance log” OR  “Compliance logs” OR “Exercise 
log” OR “Exercise logs” (“Training diaries” OR “training diary”) AND (home 
OR adherence OR exercise OR compliance) OR (“Training log” OR “training 
logs”) AND (home OR adherence OR exercise OR compliance)  
Borg scale 
 
  
TI “perceived exertion” OR  TI “Borg” OR (TI “RPE” AND AB (Borg OR 
“perceived exertion”))  
JPBA 
 
TI, AB “joint protection behaviour assessment” OR “joint protection behavior 
assessment” OR JPBA 
Yamax Digiwalker 
CW-701 
 
 
(Yamax AND (Digiwalker* OR Digi-walker)) OR (yamax AND pedometer*) OR 
((digiwalker OR digi-walker) AND pedometer*) OR ((digiwalker OR digi-
walker) AND CW*) OR (Yamax AND CW*) 
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Polar A1 & FS1 
heart rate monitors 
 
 
TI, AB (Polar AND heart AND monitor*)  
 
